

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/02, C07K 14/07/05, 19/00, A61K 38/17, 39/395, G01N 3/15/53, 3/15/65, 33/568

(52) International Application Number: PCT/GB95/00238

(53) Priority Date: 08/19/95, 06/02/95

(71) Applicant (for all designated States except US): THE BOARD OF TRUSTEES OF THE LEL AND STANFORD FUNDS OF THE UNIVERSITY OF LOS ANGELES, Suite 550, 900 Welch Road, Palo Alto, CA 94304-1850 (US).

(71) Applicant (for MG only): GREAVES, Carol Pauline [GB/GB]; 80 Church Road, Wimborne, Avon BS25 1BP (GB).

(72) Inventors and (75) Inventors/ Applicants (for US only): GODFREY, Wayne [US/US], 18000 Spurline Boulevard, Woodside, CA 94062 (US); ERLEMAN, Edna George [US/US], 60 Lane Place, Atherton, CA 94027 (US).

(74) Agent: GREAVES, Carol; Memphis Ellis, York House, 23 Kingway, London WC2B 4PF (GB).

(54) Title: LIGAND (ACT-4-L) TO A RECEPTOR ON THE SURFACE OF ACTIVATED CD4⁺ T-CELLS

(57) Abstract

The invention relates to certain specific binding partners, in particular ligands and fragments, variants, mutants or derivatives for a receptor on the surface of activated T-cells - e.g. activated CD4⁺ T-cells. Exemplary ligands are based on a ligand designated ACT-4-Lab-1. Preferred fragments include carboxyl-terminal domains of ligands. In addition the invention provides certain binding molecules with specificity for the above-named specific binding partners which code for such a specific binding partner or binding molecule as well as expression inventories under provides methods and apparatus which facilitate these. The invention further provides pharmaceutical compositions containing the specific binding partners and binding molecules in the treatment of various diseases and conditions of the immune system. Also provided by the invention are methods of monitoring activated T-cells e.g. activated CD4⁺ T-cells using the specific binding partners or fragments thereof, together with the use in those methods.

(11) International Publication Number: WO 95/21915

(13) International Publication Date: 17 August 1995 (17.08.95)

(15) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, FR, GE, HU, ID, IE, IS, KZ, KP, KR, LK, LR, LT, LU, LV, MD, MG, MN, MW, MK, NL, NO, NZ, PL, PT, RO, RU, SI, SK, TI, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, OA/PAT), patent (JP, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TU), ARIPO patent (KE, MW, SD, SZ).

(16) International Search Report

With international search report.
Before the expiration of the time limit for amending the claims and to re-establish in the event of the receipt of communications.

(21) International Filing Date: 6 February 1995 (06.02.95)

(30) Priority Date: 10 February 1994 (10.02.94) US

(31) International Publication Date: 17 August 1995 (17.08.95)

(33) International Publication Number: PCT/GB95/00238

(34) International Application Number: PCT/GB95/00238

(35) International Filing Date: 08/19/95

(36) Priority Date: 06/02/95

(37) International Publication Date: 17 August 1995 (17.08.95)

(38) International Publication Number: WO 95/21915

(39) International Publication Date: 17 August 1995 (17.08.95)

(40) International Publication Number: WO 95/21915

(41) International Publication Date: 17 August 1995 (17.08.95)

(42) International Publication Number: WO 95/21915

(43) International Publication Date: 17 August 1995 (17.08.95)

(44) International Publication Number: WO 95/21915

(45) International Publication Date: 17 August 1995 (17.08.95)

(46) International Publication Number: WO 95/21915

(47) International Publication Date: 17 August 1995 (17.08.95)

(48) International Publication Number: WO 95/21915

(49) International Publication Date: 17 August 1995 (17.08.95)

(50) International Publication Number: WO 95/21915

(51) International Publication Date: 17 August 1995 (17.08.95)

(52) International Publication Number: WO 95/21915

(53) International Publication Date: 17 August 1995 (17.08.95)

(54) International Publication Number: WO 95/21915

(55) International Publication Date: 17 August 1995 (17.08.95)

(56) International Publication Number: WO 95/21915

(57) International Publication Date: 17 August 1995 (17.08.95)

(58) International Publication Number: WO 95/21915

(59) International Publication Date: 17 August 1995 (17.08.95)

(60) International Publication Number: WO 95/21915

(61) International Publication Date: 17 August 1995 (17.08.95)

(62) International Publication Number: WO 95/21915

(63) International Publication Date: 17 August 1995 (17.08.95)

(64) International Publication Number: WO 95/21915

(65) International Publication Date: 17 August 1995 (17.08.95)

(66) International Publication Number: WO 95/21915

(67) International Publication Date: 17 August 1995 (17.08.95)

(68) International Publication Number: WO 95/21915

(69) International Publication Date: 17 August 1995 (17.08.95)

(70) International Publication Number: WO 95/21915

(71) International Publication Date: 17 August 1995 (17.08.95)

(72) International Publication Number: WO 95/21915

(73) International Publication Date: 17 August 1995 (17.08.95)

(74) International Publication Number: WO 95/21915

(75) International Publication Date: 17 August 1995 (17.08.95)

(76) International Publication Number: WO 95/21915

(77) International Publication Date: 17 August 1995 (17.08.95)

(78) International Publication Number: WO 95/21915

(79) International Publication Date: 17 August 1995 (17.08.95)

(80) International Publication Number: WO 95/21915

(81) International Publication Date: 17 August 1995 (17.08.95)

(82) International Publication Number: WO 95/21915

(83) International Publication Date: 17 August 1995 (17.08.95)

(84) International Publication Number: WO 95/21915

(85) International Publication Date: 17 August 1995 (17.08.95)

(86) International Publication Number: WO 95/21915

(87) International Publication Date: 17 August 1995 (17.08.95)

(88) International Publication Number: WO 95/21915

(89) International Publication Date: 17 August 1995 (17.08.95)

(90) International Publication Number: WO 95/21915

(91) International Publication Date: 17 August 1995 (17.08.95)

(92) International Publication Number: WO 95/21915

(93) International Publication Date: 17 August 1995 (17.08.95)

(94) International Publication Number: WO 95/21915

(95) International Publication Date: 17 August 1995 (17.08.95)

(96) International Publication Number: WO 95/21915

(97) International Publication Date: 17 August 1995 (17.08.95)

(98) International Publication Number: WO 95/21915

(99) International Publication Date: 17 August 1995 (17.08.95)

(100) International Publication Number: WO 95/21915

(101) International Publication Date: 17 August 1995 (17.08.95)

(102) International Publication Number: WO 95/21915

(103) International Publication Date: 17 August 1995 (17.08.95)

(104) International Publication Number: WO 95/21915

(105) International Publication Date: 17 August 1995 (17.08.95)

(106) International Publication Number: WO 95/21915

(107) International Publication Date: 17 August 1995 (17.08.95)

(108) International Publication Number: WO 95/21915

(109) International Publication Date: 17 August 1995 (17.08.95)

(110) International Publication Number: WO 95/21915

(111) International Publication Date: 17 August 1995 (17.08.95)

(112) International Publication Number: WO 95/21915

(113) International Publication Date: 17 August 1995 (17.08.95)

(114) International Publication Number: WO 95/21915

(115) International Publication Date: 17 August 1995 (17.08.95)

(116) International Publication Number: WO 95/21915

(117) International Publication Date: 17 August 1995 (17.08.95)

(118) International Publication Number: WO 95/21915

(119) International Publication Date: 17 August 1995 (17.08.95)

(120) International Publication Number: WO 95/21915

(121) International Publication Date: 17 August 1995 (17.08.95)

(122) International Publication Number: WO 95/21915

(123) International Publication Date: 17 August 1995 (17.08.95)

(124) International Publication Number: WO 95/21915

(125) International Publication Date: 17 August 1995 (17.08.95)

(126) International Publication Number: WO 95/21915

(127) International Publication Date: 17 August 1995 (17.08.95)

(128) International Publication Number: WO 95/21915

(129) International Publication Date: 17 August 1995 (17.08.95)

(130) International Publication Number: WO 95/21915

(131) International Publication Date: 17 August 1995 (17.08.95)

(132) International Publication Number: WO 95/21915

(133) International Publication Date: 17 August 1995 (17.08.95)

(134) International Publication Number: WO 95/21915

(135) International Publication Date: 17 August 1995 (17.08.95)

(136) International Publication Number: WO 95/21915

(137) International Publication Date: 17 August 1995 (17.08.95)

(138) International Publication Number: WO 95/21915

(139) International Publication Date: 17 August 1995 (17.08.95)

(140) International Publication Number: WO 95/21915

(141) International Publication Date: 17 August 1995 (17.08.95)

(142) International Publication Number: WO 95/21915

(143) International Publication Date: 17 August 1995 (17.08.95)

(144) International Publication Number: WO 95/21915

(145) International Publication Date: 17 August 1995 (17.08.95)

(146) International Publication Number: WO 95/21915

(147) International Publication Date: 17 August 1995 (17.08.95)

(148) International Publication Number: WO 95/21915

(149) International Publication Date: 17 August 1995 (17.08.95)

(150) International Publication Number: WO 95/21915

(151) International Publication Date: 17 August 1995 (17.08.95)

(152) International Publication Number: WO 95/21915

(153) International Publication Date: 17 August 1995 (17.08.95)

(154) International Publication Number: WO 95/21915

(155) International Publication Date: 17 August 1995 (17.08.95)

(156) International Publication Number: WO 95/21915

(157) International Publication Date: 17 August 1995 (17.08.95)

(158) International Publication Number: WO 95/21915

(159) International Publication Date: 17 August 1995 (17.08.95)

(160) International Publication Number: WO 95/21915

(161) International Publication Date: 17 August 1995 (17.08.95)

(162) International Publication Number: WO 95/21915

(163) International Publication Date: 17 August 1995 (17.08.95)

(164) International Publication Number: WO 95/21915

(165) International Publication Date: 17 August 1995 (17.08.95)

(166) International Publication Number: WO 95/21915

(167) International Publication Date: 17 August 1995 (17.08.95)

(168) International Publication Number: WO 95/21915

(169) International Publication Date: 17 August 1995 (17.08.95)

(170) International Publication Number: WO 95/21915

(171) International Publication Date: 17 August 1995 (17.08.95)

(172) International Publication Number: WO 95/21915

(173) International Publication Date: 17 August 1995 (17.08.95)

(174) International Publication Number: WO 95/21915

(175) International Publication Date: 17 August 1995 (17.08.95)

(176) International Publication Number: WO 95/21915

(177) International Publication Date: 17 August 1995 (17.08.95)

(178) International Publication Number: WO 95/21915

(179) International Publication Date: 17 August 1995 (17.08.95)

(180) International Publication Number: WO 95/21915

(181) International Publication Date: 17 August 1995 (17.08.95)

(182) International Publication Number: WO 95/21915

(183) International Publication Date: 17 August 1995 (17.08.95)

(184) International Publication Number: WO 95/21915

(185) International Publication Date: 17 August 1995 (17.08.95)

(186) International Publication Number: WO 95/21915

(187) International Publication Date: 17 August 1995 (17.08.95)

(188) International Publication Number: WO 95/21915

(189) International Publication Date: 17 August 1995 (17.08.95)

(190) International Publication Number: WO 95/21915

(191) International Publication Date: 17 August 1995 (17.08.95)

(192) International Publication Number: WO 95/21915

(193) International Publication Date: 17 August 1995 (17.08.95)

(194) International Publication Number: WO 95/21915

(195) International Publication Date: 17 August 1995 (17.08.95)

(196) International Publication Number: WO 95/21915

(197) International Publication Date: 17 August 1995 (17.08.95)

(198) International Publication Number: WO 95/21915

(199) International Publication Date: 17 August 1995 (17.08.95)

(200) International Publication Number: WO 95/21915

(201) International Publication Date: 17 August 1995 (17.08.95)

(202) International Publication Number: WO 95/21915

(203) International Publication Date: 17 August 1995 (17.08.95)

(204) International Publication Number: WO 95/21915

(205) International Publication Date: 17 August 1995 (17.08.95)

1

LIGAND (ACT-4-L) TO A RECEPTOR ON THE SURFACE
OF ACTIVATED CD4⁺ T-CELLS

CROSS-REFERENCE TO RELATED APPLICATION

5 Copending application USSN 08/147,784, filed November 3, 1993, describes related subject matter and is incorporated by reference in its entirety for all purposes.

TECHNICAL FIELD

This invention relates generally to the isolation and characterization of a ligand (ACT-4-L) to a receptor on the surface of activated CD4⁺ T-cells. This invention also provides antibodies to the ligand, and methods of using the ligand and the antibodies for monitoring and/or modulating immune responses.

BACKGROUND OF THE INVENTION

Immune responses are largely mediated by a diverse collection of peripheral blood cells termed leukocytes. The leukocytes include lymphocytes, granulocytes and monocytes. Granulocytes are further subdivided into neutrophils, eosinophils and basophils. Lymphocytes are further subdivided into T and B lymphocytes. T-lymphocytes originate from lymphocytic-committed stem cells of the embryo. Differentiation occurs in the thymus and proceeds through prothymocyte, cortical thymocyte and medullary thymocyte intermediate

2

stages, to produce various types of mature T-cells. These subtypes include CD8⁺ T cells (also known as cytotoxic/suppressor T cells), which, when activated, have the capacity to lyse target cells, and CD4⁺ T cells (also known as T helper and T inducer cells), which, when activated, have the capacity to stimulate other immune system cell types.

Immune system responses are elicited in several differing situations. The most frequent response is as a desirable protection against infectious microorganisms. However, undesired immune response can occur following transplantation of foreign tissue, or in an autoimmune disease, in which one of a body's own antigens is the target for the immune response. Immune responses can also be initiated *in vitro* by mitogens or antibodies against certain receptors. In each of these situations, an immune response is transduced from a stimulating event via a complex interaction of leukocytic cell types.

However, the participating cell types and nature of the interaction between cell types may vary for different stimulating events. For example, immune responses against invading bacteria are often transduced by formation of complexes between an MHC Class II receptor and a bacterial antigen, which then activate CD4⁺ T-cells. By contrast, immune responses against viral infections are principally transduced by formation of MHC Class I/viral antigen complexes and subsequent activation of CD8⁺ cells.

5

10

15

20

25

3

Over recent years, many leukocyte cell surface antigens have been identified, some of which have been shown to have a role in signal transduction. It has been found that signals may be transduced between a cell-surface receptor and either a soluble ligand or a cell-surface-bound ligand. The amino acid sequences of leukocyte surface molecules comprise a number of characteristic recurring sequences or motifs. These motifs are predicted to be related in evolution, have similar folding patterns and mediate similar types of interactions. A number of superfamilies, including the immunoglobulin and nerve growth factor receptor superfamilies, have been described. Members of the nerve growth factor receptor family include NGFR, found on neural cells; the B-cell antigen CD40; the rat OX-40 antigen, found on activated CD4⁺ cells (Mallet et al., EMBO J. 9:1063-1068 (1990) (hereby incorporated by reference for all purposes); two receptors for tumor necrosis factor (TNF), LTNFR-I and TNFR-II, found on a variety of cell types; 4-1BB found on T-cells; SFV-T2, an open reading frame in Shape fibroma virus; and possibly fas, CD27 and CD30. See generally Mallet & Barclay, Immunology Today 12:220-222 (1990) (hereby incorporated by reference for all purposes).

The identification of cell-surface receptors has suggested new agents for suppressing undesirable immune responses such as transplant rejection, autoimmune disease and inflammation. Agents, particularly

4

antibodies, that block receptors of immune cells from binding to soluble molecules or cell-bound receptors can impair immune responses. Ideally, an agent should block only undesired immune responses (e.g., transplant rejection) while leaving a residual capacity to effect desirable responses (e.g., responsive to pathogenic microorganisms). The immunosuppressive action of some agents, for example, antibodies against the CD3 receptor and the IL-2 receptor have already been tested in clinical trials. Although some trials have shown encouraging results, significant problems remain. First, a patient may develop an immune response toward the blocking agent preventing continued immunosuppressive effects unless different agents are available. Second, cells expressing the target antigen may be able to adapt to the presence of the blocking agent by ceasing to express the antigen, while retaining immune functions. In this situation, continued treatment with a single immunosuppressive agent is ineffective. Third, many targets for therapeutic agents are located on more than one leukocyte subtype, with the result that it is generally not possible to selectively block or eliminate the response of only specific cellular subtypes and thereby leave unimpaired a residual immune capacity for combating infectious microorganisms.

Based on the foregoing it is apparent that a need exists for additional and improved agents capable of suppressing immune responses, particularly agents capable of

5

10

15

20

25

selective suppression. The present invention fulfills these and other needs, in part, by providing a ligand (ACT-4-L) to a receptor localized on activated human CD4⁺ T-lymphocytes.

The complete amino acid sequence as shown in Fig 10 is disclosed in Muira et al., Mol. Cell Biol. 11 (1991) 1313-1325 as comprising a gp34 protein but no utility is assigned to this protein. Antibodies were raised against this protein.

SUMMARY OF THE INVENTION

The invention provides a specific binding partner for an ACT-4 receptor polypeptide which (a) is other than the monoclonal antibody designated 1106 produced by the hybridoma FBL106 deposited as

ATCC #B11483; and

(b) has an amino acid sequence other than the complete amino acid sequence shown in Figure 10.

In particular the invention relates to purified ACT-4-L ligand polypeptides which are other than antibodies. Suitably the specific binding partners comprise a fragment, variant, mutant or derivative of the amino acid sequence shown in Figure 10 or a homologue of analogue thereof; optionally in the form of a conjugate or complex. The specific binding partners may comprise polypeptides having a segment or at least 5 and suitably between 5-160 contiguous amino acids from the amino acids of an exemplified ACT-4-L ligand designated ACT-4-L-h-1 and shown in Figure 10. The polypeptides usually exhibit

6

at least 80% sequence identity to the ACT-4-h-L-1 sequence and often share an antigenic determinant in common with the ACT-4-L-h-1 ligand. The polypeptides usually comprise an intracellular domain, a transmembrane domain or an extracellular domain, preferably an extracellular domain.

The invention also provides purified extracellular domains of ACT-4-L ligands. These domains comprise at least five contiguous amino acids from the downstream of the SmaI site of the nucleic acid sequence shown in Figure 10. Some of these extracellular domains are full-length. Other extracellular domains are fragments of full-length domains. Some extracellular domains specifically bind to the ACT-4-L-h-1 ligand. Other extracellular domains specifically bind to an exemplified receptor of ACT-4-L-h-1, the receptor being designated ACT-4-h-1. Some extracellular domains consist essentially of a domain possessing a particular functional property, for example, the capacity to specifically bind to the ACT-4-h-1 receptor. Thus the invention also provides an extracellular domain comprising at least five contiguous amino acids from the extracellular domain of the protein shown in Figure 10, or mutants, variants or derivatives thereof, that can bind to ACT-4.

Some specific binding partners such as

7

extracellular domains inhibit in vitro activation of CD4⁺ T-cells expressing the ACT-4-h-1 receptor on their surface. Other specific binding partners such as extracellular domains stimulate in vitro activation of such T-cells. Where the specific binding partner is a ligand fragment, it may compete with the specific binding partner shown in Figure 10 for binding to an antibody.

Any of the above specific binding partners including extracellular domains may further comprise a linked second polypeptide which may be covalently conjugated or form part of a fusion protein. Examples of suitable linked polypeptides include the constant region of an immunoglobulin heavy chain, as well as toxins or labels.

The specific binding partners of the invention are suitably in soluble form and may be labelled. In particular the invention provides a soluble polypeptide which is a specific binding agent capable of specific binding with ACT-4. Such a polypeptide will have the amino acid sequence of Figure 10 except for the transmembrane subsequence thereof.

The invention also provides an ACT-4 receptor polypeptide consisting essentially of a domain that specifically binds to the ACT-4-L-h-1 ligand. The invention also concerns binding moieties such as antibodies that specifically bind to ACT-4-L-h-1, preferably to an extracellular domain thereof.

The invention further provides a binding moiety

8

with specificity for any of the above-described specific binding partners, which binding moiety is other than the ACT-4 receptor polypeptide and which is not cross reactive with a polypeptide which has the complete amino acid sequence shown in Figure 10.

Suitably the binding moiety comprises an antibody binding domain.

In addition the invention provides a binding moiety with specificity for an ACT-4 receptor polypeptide which comprises: (a) part or all of a human antibody binding domain or (b) a humanised portion of an antibody. Preferred antibodies are humanized antibodies, such as an antibody comprising a humanised portion and a non-human antibody binding domain, and human antibodies.

Examples of humanised antibodies are described in more detail hereinafter.

The binding moieties have a variety of binding specificities. For example, some humanized antibodies specifically bind to the ACT-4-L-h-1 ligand on the surface of a B-cell so as to inhibit activation of the B cell. Other antibodies stimulate activation of B-cells. Other antibodies specifically bind to the ACT-4-L-h-1 ligand on the surface of a B-cell so as to inhibit the capacity of the B-cell to activate CD4⁺ T-cells.

The antibodies may be monoclonal antibodies. The binding moieties may comprise a Fab or F(ab)'2 of an antibody.

A further aspect of the invention comprises

9

5 extracellular domains stimulate in vitro activation of ACT-4 receptor polypeptide and which is not cross reactive with a polypeptide which has the complete amino acid sequence shown in Figure 10.

Suitably the binding moiety comprises an antibody binding domain.

In addition the invention provides a binding moiety with specificity for an ACT-4 receptor polypeptide which comprises: (a) part or all of a human antibody binding domain or (b) a humanised portion of an antibody. Preferred antibodies are humanized antibodies, such as an antibody comprising a humanised portion and a non-human antibody binding domain, and human antibodies.

Examples of humanised antibodies are described in more detail hereinafter.

The binding moieties have a variety of binding specificities. For example, some humanized antibodies specifically bind to the ACT-4-L-h-1 ligand on the surface of a B-cell so as to inhibit activation of the B cell. Other antibodies stimulate activation of B-cells. Other antibodies specifically bind to the ACT-4-L-h-1 ligand on the surface of a B-cell so as to inhibit the capacity of the B-cell to activate CD4⁺ T-cells.

The antibodies may be monoclonal antibodies. The binding moieties may comprise a Fab or F(ab)'2 of an antibody.

A further aspect of the invention comprises

10

linked second polypeptide which may be covalently conjugated or form part of a fusion protein. Examples of suitable linked polypeptides include the constant region of an immunoglobulin heavy chain, as well as toxins or labels.

Examples of humanised antibodies are described in more detail hereinafter.

The binding moieties have a variety of binding specificities. For example, some humanized antibodies specifically bind to the ACT-4-L-h-1 ligand on the surface of a B-cell so as to inhibit activation of the B cell. Other antibodies stimulate activation of B-cells. Other antibodies specifically bind to the ACT-4-L-h-1 ligand on the surface of a B-cell so as to inhibit the capacity of the B-cell to activate CD4⁺ T-cells.

The antibodies may be monoclonal antibodies. The binding moieties may comprise a Fab or F(ab)'2 of an antibody.

A further aspect of the invention comprises

15

linked second polypeptide which may be covalently conjugated or form part of a fusion protein. Examples of suitable linked polypeptides include the constant region of an immunoglobulin heavy chain, as well as toxins or labels.

Examples of humanised antibodies are described in more detail hereinafter.

The binding moieties have a variety of binding specificities. For example, some humanized antibodies specifically bind to the ACT-4-L-h-1 ligand on the surface of a B-cell so as to inhibit activation of the B cell. Other antibodies stimulate activation of B-cells. Other antibodies specifically bind to the ACT-4-L-h-1 ligand on the surface of a B-cell so as to inhibit the capacity of the B-cell to activate CD4⁺ T-cells.

The antibodies may be monoclonal antibodies. The binding moieties may comprise a Fab or F(ab)'2 of an antibody.

A further aspect of the invention comprises

20

linked second polypeptide which may be covalently conjugated or form part of a fusion protein. Examples of suitable linked polypeptides include the constant region of an immunoglobulin heavy chain, as well as toxins or labels.

Examples of humanised antibodies are described in more detail hereinafter.

The binding moieties have a variety of binding specificities. For example, some humanized antibodies specifically bind to the ACT-4-L-h-1 ligand on the surface of a B-cell so as to inhibit activation of the B cell. Other antibodies stimulate activation of B-cells. Other antibodies specifically bind to the ACT-4-L-h-1 ligand on the surface of a B-cell so as to inhibit the capacity of the B-cell to activate CD4⁺ T-cells.

The antibodies may be monoclonal antibodies. The binding moieties may comprise a Fab or F(ab)'2 of an antibody.

A further aspect of the invention comprises

25

linked second polypeptide which may be covalently conjugated or form part of a fusion protein. Examples of suitable linked polypeptides include the constant region of an immunoglobulin heavy chain, as well as toxins or labels.

Examples of humanised antibodies are described in more detail hereinafter.

The binding moieties have a variety of binding specificities. For example, some humanized antibodies specifically bind to the ACT-4-L-h-1 ligand on the surface of a B-cell so as to inhibit activation of the B cell. Other antibodies stimulate activation of B-cells. Other antibodies specifically bind to the ACT-4-L-h-1 ligand on the surface of a B-cell so as to inhibit the capacity of the B-cell to activate CD4⁺ T-cells.

The antibodies may be monoclonal antibodies. The binding moieties may comprise a Fab or F(ab)'2 of an antibody.

A further aspect of the invention comprises

9

nucleic acid segments which either code for the specific binding partner of an ACT-4 receptor (other than a nucleic acid segment encoding for the complete amino acid sequence shown in Figure 10), such as those described above, or for the binding moieties described above. These nucleic acid segments may be used in the preparation of the respective proteins by incorporation into an appropriate replicable expression vector and incorporation into a host cell which is a prokaryotic or eukaryotic cell which are then cultured. Cell lines and vectors which are involved in this process form further aspects of the invention.

In another aspect, the invention relates to pharmaceutical compositions. The invention provides a pharmaceutical composition comprising a specific binding partner for an ACT-4 receptor which is other than the monoclonal antibody designated Li06 produced by the hybridoma HB1106 deposited as ATCC HB11483; in combination with a pharmaceutically acceptable carrier. The pharmaceutical compositions suitably comprise a pharmaceutically active carrier and an agent that specifically binds to an extracellular domain of the ACT-4-L-h-1 ligand as described above. Alternatively the invention provides a pharmaceutical composition comprising a specific binding partner for a ACT-4 receptor which has the amino acid sequence shown in Figure 10 or fragment, variant, mutant or derivative thereof, in combination with a pharmaceutically

10

acceptable carrier. Suitable binding moieties are those described above.

A suitable composition comprises a specific binding partner as described above or a specific binding partner polypeptide having the complete amino acid sequence shown in Figure 10, carried on the surface of a preparation of liposomes, e.g. by a transmembrane sequence.

The invention further provides methods of modifying an immune response in a patient, for example, suppressing the immune response, the methods comprising administering an effective amount of a pharmaceutical composition such as those described above. The administration may be carried out ex vivo. Preferred agents are monoclonal antibodies, ACT-4-L ligand polypeptides and ACT-4 receptor polypeptides. The invention provides other methods of suppressing an immune response in which the agent competes with the ACT-4-L-h-1 ligand for specific binding to the ACT-4-h-1 receptor. The methods are useful in the treatment of a patient having an immune disease or condition. Examples of conditions where these methods may be useful include transplant rejection, GVHD, autoimmune disease, inflammation, infectious agents, HTLV infected cells or HIV as well as inflammatory bowel disease or disorder.

The invention also provides a method of screening for immunomodulating agents able to recognise ACT-4, the method comprising:

5

10

modifying an immune response in a patient, for example, suppressing the immune response, the methods comprising administering an effective amount of a pharmaceutical composition such as those described above. The administration may be carried out ex vivo. Preferred

15

agents are monoclonal antibodies, ACT-4-L ligand polypeptides and ACT-4 receptor polypeptides. The invention provides other methods of suppressing an immune response in which the agent competes with the ACT-4-L-h-1 ligand for specific binding to the ACT-4-h-1 receptor.

20

The methods are useful in the treatment of a patient having an immune disease or condition. Examples of conditions where these methods may be useful include transplant rejection, GVHD, autoimmune disease,

inflammation, infectious agents, HTLV infected cells or

25

HIV as well as inflammatory bowel disease or disorder.

The invention also provides a method of screening for immunomodulating agents able to recognise ACT-4, the method comprising:

11

contacting a specific binding partner for an ACT-4 receptor polypeptide with a material to be tested; and detecting binding between the specific binding partner and the agent, the material under test.

Alternatively the invention provides a method of screening for immunomodulatory agents able to affect the recognition of ACT-4 receptor polypeptide by its specific binding partner, the method comprising: contacting together (a) a specific binding partner for an ACT-4 receptor polypeptide, (b) an ACT-4 receptor or specific binding analogue thereof, and (c) an agent under test; and detecting binding between components (a) and (b). Suitably the specific binding partner for the ACT-4 receptor is immobilised to a solid surface.

The methods can be utilised for the screening for immunosuppressive agents in which case the methods comprise contacting specific binding partner in particular an ACT-4-L-h-1 ligand polypeptide with a potential immunosuppressive agent. Specific binding between the ACT-4-L-h-1 ligand polypeptide and the agent is detected. The specific binding is indicative of immunosuppressive activity.

In a further aspect the invention provides a method of inducing an immune response to a selected antigen comprising: administering a suitable binding moiety as described above to a patient; and exposing the patient to the selected antigen.

12

The invention also provides methods of monitoring activated CD4⁺ T-cells. The methods comprise contacting a cells, such as a tissue sample from a patient, with a specific binding partner for an ACT-4 receptor such as an ACT-4-L ligand polypeptide that specifically binds to an extracellular domain of the ACT-4-h-1 receptor. Specific binding between the ACT-4-L ligand polypeptide and the tissue sample is detected to indicate the presence of the activated CD4⁺ T-cells. The method is suitably effected *in vitro*.

In a further aspect the invention provides a method of inhibiting infection of CD4⁺ T-cells by a human immune deficiency virus, the method comprising contacting the CD4⁺ T-cells with an antibody that specifically binds to an extracellular domain of the ACT-4 receptor.

The invention further provides a kit for detecting activated CD4⁺ T-cells which comprises a specific binding partner for ACT-4 receptor as described above.

Another aspect of the invention comprised the use of polypeptide having amino acid sequence as shown in Figure 10 or specific binding partners according to claim 1 in specific binding reactions for recognition of ACT-4 receptors or of specific binding analogues thereof.

Alternatively the invention provides the use of ACT-4 receptors or specific binding analogues thereof in specific binding reactions for recognition of polypeptides having the amino acid sequence shown in

13

monitoring activated CD4⁺ T-cells. The methods comprise contacting a cells, such as a tissue sample from a patient, with a specific binding partner for an ACT-4 receptor such as an ACT-4-L ligand polypeptide that specifically binds to an extracellular domain of the ACT-4-h-1 receptor. Specific binding between the ACT-4-L ligand polypeptide and the tissue sample is detected to indicate the presence of the activated CD4⁺ T-cells. The method is suitably effected *in vitro*.

14

In a further aspect the invention provides a method of inhibiting infection of CD4⁺ T-cells by a human immune deficiency virus, the method comprising contacting the CD4⁺ T-cells with an antibody that specifically binds to an extracellular domain of the ACT-4 receptor.

The invention further provides a kit for detecting activated CD4⁺ T-cells which comprises a specific binding partner for ACT-4 receptor as described above.

15

Another aspect of the invention comprised the use of polypeptide having amino acid sequence as shown in Figure 10 or specific binding partners according to claim 1 in specific binding reactions for recognition of ACT-4 receptors or of specific binding analogues thereof.

Alternatively the invention provides the use of ACT-4 receptors or specific binding analogues thereof in specific binding reactions for recognition of polypeptides having the amino acid sequence shown in

25

16

13

Figure 10 or of specific binding partners according to claim 1.

The invention further provides a method of detecting an analyte which comprises a specific binding partner for an ACT-4 receptor e.g. in a tissue sample such as a biopsy sample or a blood sample; which method comprises contacting the analyte with a first reagent comprising a specific binding agent that can recognize the analyte, with a second reagent comprising a specific binding agent of similar or of complementary binding specificity as the analyte, there being provided a label for the second reagent, and detecting or quantitating the specific binding of the second reagent to its partner.

A further method for the invention is for detecting an analyte which comprises a substance having complementary binding specificity to a specific binding partner for an ACT-4 receptor e.g. in a tissue sample such as a biopsy sample or a blood sample, which method comprises contacting the analyte with a first reagent comprising a specific binding partner for an ACT-4 receptor, a second reagent comprising a specific binding agent or similar or of complementary binding specificity as the analyte, there being provided a label for the second reagent, and detecting or quantitating the specific binding of the second reagent to its partner.

These methods can be used in the diagnosis or detection of for example an inflammatory condition, e.g. an inflammatory bowel disease or disorder. They can be

14

carried out on a biopsy sample from a patient suspected of having an inflammatory condition.

In addition the invention provides a kit for carrying out a specific binding assay for detection or quantitation of an analyte that comprises a specific binding partner for an ACT-4 receptor, or an ACT-4 receptor or a specific binding analogue thereof; wherein said kit comprises a first reagent comprising a specific binding agent that can recognize the analyte, a second reagent comprising a specific binding agent of similar or of complementary binding specificity as the analyte, and a label (e.g. a radioactive or enzyme label) for the second reagent.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1: Two-color staining of peripheral blood lymphocytes to analyze expression of ACT-4-h-1 on different cell types.

Fig. 2: Kinetics of ACT-4-h-1 expression on alloantigen-activated CD4⁺ T-cells. MCF = Mean channel fluorescence.

Fig. 3: Kinetics of ACT-4-h-1 expression on tetanus-toxoid-activated CD4⁺ T-cells.

Fig. 4: Kinetics of ACT-4-h-1 expression on PHA-activated CD4⁺ T-cells.

Fig. 5: cDNA (upper) and deduced amino acid sequence (lower) of ACT-4-h-1. The Figure indicates the locations of an N-terminal signal sequence, two possible signal cleavage sites (vertical arrows), two

15

quantitative binding assay for detection or

5 quantitation of an analyte that comprises a specific

binding partner for an ACT-4 receptor, or an ACT-4

receptor or a specific binding analogue thereof; wherein

said kit comprises a first reagent comprising a specific

binding agent that can recognize the analyte, a second

10 reagent comprising a specific binding agent of similar or

of complementary binding specificity as the analyte, and

a label (e.g. a radioactive or enzyme label) for the

second reagent.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1: Two-color staining of peripheral blood lymphocytes to analyze expression of ACT-4-h-1 on different cell types.

Fig. 2: Kinetics of ACT-4-h-1 expression on alloantigen-activated CD4⁺ T-cells. MCF = Mean channel fluorescence.

Fig. 3: Kinetics of ACT-4-h-1 expression on tetanus-toxoid-activated CD4⁺ T-cells.

Fig. 4: Kinetics of ACT-4-h-1 expression on PHA-activated CD4⁺ T-cells.

Fig. 5: cDNA (upper) and deduced amino acid sequence (lower) of ACT-4-h-1. The Figure indicates the locations of an N-terminal signal sequence, two possible signal cleavage sites (vertical arrows), two

15

lymphocytes to analyze expression of ACT-4-h-1 on different cell types.

Fig. 2: Kinetics of ACT-4-h-1 expression on

alloantigen-activated CD4⁺ T-cells. MCF = Mean channel

fluorescence.

Fig. 3: Kinetics of ACT-4-h-1 expression on

tetanus-toxoid-activated CD4⁺ T-cells.

Fig. 4: Kinetics of ACT-4-h-1 expression on

PHA-activated CD4⁺ T-cells.

Fig. 5: cDNA (upper) and deduced amino acid

sequence (lower) of ACT-4-h-1. The Figure indicates the

locations of an N-terminal signal sequence, two possible

signal cleavage sites (vertical arrows), two

20

lymphocytes to analyze expression of ACT-4-h-1 on different cell types.

Fig. 2: Kinetics of ACT-4-h-1 expression on

alloantigen-activated CD4⁺ T-cells. MCF = Mean channel

fluorescence.

Fig. 3: Kinetics of ACT-4-h-1 expression on

tetanus-toxoid-activated CD4⁺ T-cells.

Fig. 4: Kinetics of ACT-4-h-1 expression on

PHA-activated CD4⁺ T-cells.

Fig. 5: cDNA (upper) and deduced amino acid

sequence (lower) of ACT-4-h-1. The Figure indicates the

locations of an N-terminal signal sequence, two possible

signal cleavage sites (vertical arrows), two

25

lymphocytes to analyze expression of ACT-4-h-1 on different cell types.

Fig. 2: Kinetics of ACT-4-h-1 expression on

alloantigen-activated CD4⁺ T-cells. MCF = Mean channel

fluorescence.

Fig. 3: Kinetics of ACT-4-h-1 expression on

tetanus-toxoid-activated CD4⁺ T-cells.

Fig. 4: Kinetics of ACT-4-h-1 expression on

PHA-activated CD4⁺ T-cells.

Fig. 5: cDNA (upper) and deduced amino acid

sequence (lower) of ACT-4-h-1. The Figure indicates the

locations of an N-terminal signal sequence, two possible

signal cleavage sites (vertical arrows), two

15

glycosylation sites (gly), a transmembrane domain (TM), a stop codon and a poly-A signal sequence.

Fig. 6: Construction of expression vector for production of stable transfecants expressing ACT-4-h-1.

Fig. 7: FACS™ analysis showing expression of ACT-4-h-1 on stable transfecants of COS-7, Jurkat and SP2/O cell lines.

Fig. 8: Fusion of an ACT-4-h-1 extracellular domain with an immunoglobulin heavy chain constant region to form a recombinant globulin.

Fig. 9: Schematic topographical representation of recombinant globulin formed from fusion of an ACT-4-h-1 extracellular domain with an immunoglobulin heavy chain constant region to form a recombinant globulin.

Fig. 10: cDNA sequence and predicted amino acid sequence of ACT-4-L-h-1. Boxed regions designate a transmembrane domain, four glycosylation sites and a poly-A signal.

DEFINITIONS

Abbreviations for the twenty naturally occurring amino acids follow conventional usage (*Immunology - A Synthesis*, (B.S. Golub & D.R. Green, eds., Sinauer Associates, Sunderland, MA, 2nd ed., 1991) hereby incorporated by reference for all purposes). Stereoisomers (e.g., D-amino acids) of the twenty conventional amino acids, unnatural amino acids such as α,α -disubstituted amino acids, N-alkyl amino acids,

16

lactic acid, and other unconventional amino acids may also be suitable components for polypeptides of the present invention. Examples of unconventional amino acids include: 4-hydroxyproline, γ -carboxyglutamate, ϵ -N,N-trimethyllysine, ϵ -N-acetyllysine, O-phosphoserine, N-acetylsarcosine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, ω -N-methylarginine, and other similar amino acids and imino acids (e.g., 4-hydroxyproline). In the polypeptide notation used herein, the left-hand direction is the amino terminal direction and the right-hand direction is the carboxy-terminal direction, in accordance with standard usage and convention.

Similarly, unless specified otherwise, the lefthand end of single-stranded polynucleotide sequences is the 5' end; the lefthand direction of double-stranded polynucleotide sequences is referred to as the 5' direction. The direction of 5' to 3' addition of nascent RNA transcripts is referred to as the transcription direction; sequence regions on the DNA strand having the same sequence as the RNA and which are 5' to the 5' end of the RNA transcript are referred to as "upstream sequences"; sequence regions on the DNA strand having the same sequence as the RNA and which are 3' to the 3' end of the RNA transcript are referred to as "downstream sequences".

The phrase "polynucleotide sequence" refers to a single or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the

5' to the 3' end. It includes self-replicating plasmids, infectious polymers of DNA or RNA and non-functional DNA or RNA.

The following terms are used to describe the

sequence relationships between two or more

polynucleotides: "reference sequence", "comparison window", "sequence identity", "percentage of sequence identity", and "substantial identity". A "reference sequence" is a defined sequence used as a basis for a sequence comparison; a reference sequence may be a subset of a larger sequence, for example, as a segment of a full-length cDNA or gene sequence given in a sequence listing, such as a polynucleotide sequence shown in Fig. 5 or Fig. 10, or may comprise a complete cDNA or gene sequence. Generally, a reference sequence is at least 20 nucleotides in length, frequently at least 25 nucleotides in length, and often at least 50 nucleotides in length. Since two polynucleotides may each (1) comprise a sequence (i.e., a portion of the complete polynucleotide sequence) that is similar between the two polynucleotides, and (2) may further comprise a sequence that is divergent between the two polynucleotides, sequence comparisons between two (or more)

nucleotide positions wherein a polynucleotide sequence may be compared to a reference sequence of at least 20 contiguous nucleotides and wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) of 20 percent or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Optimal alignment of sequences for aligning a comparison window may be conducted by the local homology algorithm of Smith & Waterman, *Appl. Math.* 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson & Lipman, *Proc. Natl. Acad. Sci. (USA)* 85:2444 (1988), by computerized implementations of these algorithms (FASTDB (Intelligenetics), BLAST (National Center for Biomedical Information) or GAP, BESTFIT, FASTA, and TFASTA (Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Dr., Madison, WI)), or by inspection, and the best alignment (i.e., resulting in the highest percentage of sequence similarity over the comparison window) generated by the various methods is selected. The term "sequence identity" means that two polynucleotide sequences are identical (i.e., on a nucleotide-by-nucleotide basis) over the window of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over the window of

19

comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The terms "substantial identity" as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 70, 80 or 85 percent sequence identity, preferably at least 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison window of at least 20 nucleotide positions, frequently over a window of at least 25-50 nucleotides, wherein the percentage of sequence identity is calculated by comparing the reference sequence to the polynucleotide sequence which may include deletions or additions which total 20 percent or less of the reference sequence over the window of comparison. The reference sequence may be a subset of a larger sequence, for example, as a segment of the full-length ACT-4-h-1 sequence shown in Fig. 5 or a segment of the full-length ACT-4-h-1 sequence shown in Fig. 10.

As applied to polypeptides, the term "substantial identity" means that two peptide sequences, when optimally aligned, such as by the programs BLAZE

20

(Intelligenetics) GAP or BESTFIT using default gap weights, share at least 70 percent or 80 percent sequence identity, preferably at least 90 percent sequence identity, more preferably at least 95 percent sequence identity or more (e.g., 99 percent sequence identity). Preferably, residue positions which are not identical differ by conservative amino acid substitutions. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine.

The term "substantially pure" means an object species is the predominant species present (i.e., on a molar basis it is more abundant than any other individual species in the composition), and preferably a substantially purified fraction is a composition wherein

25

As applied to polypeptides, the term "substantial identity" means that two peptide sequences, when optimally aligned, such as by the programs BLAZE

the object species comprises at least about 50 percent (on a molar basis) of all macromolecular species present. Generally, a substantially pure composition will comprise more than about 80 to 90 percent of all macromolecular species present in the composition. Most preferably, the object species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) wherein the composition consists essentially of a single macromolecular species.

The term "naturally-occurring" as used herein as applied to an object refers to the fact that an object can be found in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory is naturally-occurring.

The term "epitope" includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.

Specific binding exists when the dissociation constant for a dimeric complex is $\leq 1 \mu\text{M}$, preferably $\leq 100 \text{nM}$ and most preferably $\leq 1 \text{nM}$.

The term "higher cognate variants" as used herein refers to a gene sequence that is evolutionarily and functionally related between humans and higher mammalian species, such as primates, porcines and bovines. The term does not include gene sequences from rodents, such as rats. Thus, the cognate primate gene to the ACT-4-h-1 gene is the primate gene which encodes an expressed protein which has the greatest degree of sequence identity to the ACT-4-h-1 receptor protein and which exhibits an expression pattern similar to that of the ACT-4-h-1 protein (i.e., expressed on activated CD4⁺ cells). Similarly, the cognate primate gene to the ACT-4-L-h-1 gene is the gene whose expressed protein shows greatest sequence identity to the ACT-4-L-h-1 ligand protein and which exhibits a similar expression pattern (i.e., expressed on activated B-cells).

A population of cells is substantially enriched in a selected cell type when that cell type constitutes at least 30, 50 or 70% of the population.

The term "patient" includes human and veterinary subjects.

A test substance competes with a reference for specific binding to an antigen when an excess of the test substance substantially inhibits binding of the reference substance in a competition assay. Numerous types of competition assay including radioimmunoassay and ELISA are available. See Harlow & Lane, *Antibodies, A Laboratory Manual*, Cold Spring Harbor (1988). Substantially inhibits means that

23

the test substance reduces specific binding of the reference usually by at least 10%, 25%, 50%, 75%, or 90%. Test substances identified by a competition assay include those binding to the same epitope as the reference and those binding to an adjacent epitope sufficiently proximal to that of the epitope bound by the reference antibody for steric hindrance to occur.

DETAILED DESCRIPTION

I. ACT-4 Receptor Polypeptides

According to one embodiment of the invention, receptors on the surface of activated CD4⁺ T-cells (referred to as ACT-4 receptors) and fragments thereof are provided. The term ACT-4 receptor polypeptide is used generically to encompass full-length proteins and fragments thereof. The term ACT-4 receptor is usually reserved for full-length proteins. The amino acid sequence of the first ACT-4 receptor to be characterized [hereinafter ACT-4-h-1] is shown in Fig. 5. The suffix -h designates human origin and the suffix -1 indicates that ACT-4-h-1 is the first ACT-4 receptor to be characterized. The term ACT-4 receptor refers not only to the protein having the sequence shown in Fig. 5, but also to other proteins that represent allelic, nonallelic, and higher cognate variants of ACT-4-h-1, and natural or induced mutants of any of these. Usually, ACT-4 receptor polypeptides will also show substantial sequence identity with the ACT-4-h-1 sequence.

24

Typically, an ACT-4 receptor polypeptide will contain at least 4 and more commonly 5, 6, 7, 10 or 20, 50 or more contiguous amino acids from the ACT-4-h-1 sequence. It is well known in the art that functional domains, such as 5 binding domains or epitopes can be formed from as few as four amino acids residues.

ACT-4 receptor polypeptides will typically exhibit substantial amino acid sequence identity with the amino acid sequence of ACT-4-h-1, and be encoded by 10 nucleotide sequences that exhibit substantial sequence identity with the nucleotide sequence encoding ACT-4-h-1 shown in Fig. 5. The nucleotides encoding ACT-4 receptor proteins will also typically hybridize to the ACT-4-h-1 sequence under stringent conditions. However, these 15 nucleotides will not usually hybridize under stringent conditions to the nucleic acid encoding OX-40 receptor, as described by Mallet et al., *EMBO J.* 9:1063-68 (1990) (hereby incorporated by reference for all purposes) (See particularly Figure 2A of the Mallet et al. reference). Stringent conditions are sequence dependent and will be 20 different in different circumstances. Generally, stringent conditions are selected to be about 5° C lower than the thermal melting point (*T_m*) for the specific sequence at a defined ionic strength and pH. The *T_m* is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Typically, stringent conditions will be those in which the salt concentration is at least

25

about 0.02 molar at pH 7 and the temperature is at least about 60°C. As other factors may significantly affect the stringency of hybridization, including, among others, base composition and size of the complementary strands, the presence of organic solvents and the extent of base mismatching, the combination of parameters is more important than the absolute measure of any one.

Usually, ACT-4 receptor polypeptides will share at least one antigenic determinant in common with ACT-4-h-1 but will not be specifically reactive with antibodies against the rat OK-40 polypeptide. The existence of a common antigenic determinant is evidenced by cross-reactivity of the variant protein with any antibody prepared against ACT-4-h-1 (see Section IV). Cross-reactivity is often tested using polyclonal sera against ACT-4-h-1, but can also be tested using one or more monoclonal antibodies against ACT-4-h-1, such as the antibody designated L106.

Often ACT-4 receptor polypeptides will contain modified polypeptide backbones. Modifications include chemical derivatizations of polypeptides, such as acetylations, carboxylations and the like. They also include glycosylation modifications (N- and O-linked) and processing variants of a typical polypeptide. These processing steps specifically include enzymatic modifications, such as ubiquitination and phosphorylation. See, e.g., Hershko & Ciechanover, Ann. Rev. Bioch. 51:335-364 (1992). The ACT-4-h-1 protein,

26

for example, is heavily modified in that the observed molecular weight is about 50 kDa, whereas the predicted molecular weight based on amino acid sequence is only 27 kDa. Two putative glycosylation sites have been identified in its extracellular domain.

ACT-4 receptors likely share some or all of the topological features found for ACT-4-h-1. The amino acid sequence for ACT-4-h-1 contains a 22 or 24 amino acid putative N-terminal signal sequence. The 24 amino acid sequence is more probably based on the criteria of von Heijne, Nucleic Acids Res. 14:4683-4690 (1986) (incorporated by reference for all purposes). The ACT-4-h-1 receptor contains a single additional hydrophobic stretch of 27 amino acids spanning residues 213-240. The hydrophobic stretch probably corresponds to a transmembrane domain and its existence is consistent with ACT-4-h-1 being a type I integral membrane protein (i.e., having a single transmembrane domain with the N-terminal domain comprising the extracellular region and the C-terminus comprising the intracellular region). The 189 or 191 amino acids (depending on the exact location of the signal cleavage site) of ACT-4-h-1 amino-proximal to the transmembrane segment are designated the extracellular domain, while the 37 amino acids carboxy-proximal to the transmembrane segment are designated the intracellular domain. From the amino-terminus, the extracellular domain has an NH₂-terminal hydrophobic putative signal sequence, and three

27

intrachain loops formed by disulfide bonding between paired cysteine residues.

The topological arrangement of ACT-4 receptor polypeptides is similar to that of other members of the nerve growth factor receptor family, particularly to the rat OK-40 receptor. However, the other members show some divergence in the number of extracellular disulfide loops and glycosylation sites and in the size of the intracellular domain. See Mallet & Barclay, *supra*.

Although not all of the domains discussed above are necessarily present in all ACT-4 receptor polypeptides, an extracellular domain is expected to be present in most. Indeed, in some ACT-4 receptor polypeptides, it is possible that only an extracellular domain is present, and the natural state of such proteins is not as cell-surface bound proteins, but as soluble proteins, for example, dispersed in an extracellular body fluid. The existence of soluble variant forms has been observed for other cell surface receptors, including one member of the nerve growth factor receptor family, SFV-T2. See Mallet & Barclay, *supra*.

Besides substantially full-length polypeptides, the present invention provides for biologically active fragments of the polypeptides. Significant biological activities include receptor binding, antibody binding (e.g., the fragment competes with an intact ACT-4 receptor for specific binding to an antibody), immunogenicity (i.e., possession of epitopes that

28

stimulate B or T cell responses against the fragment), and agonism or antagonism of the binding of an ACT-4 receptor polypeptide to its ligands. A segment of an ACT-4 receptor protein or a domain thereof will ordinarily comprise at least about 5, 7, 9, 11, 13, 16, 20, 40, or 100 contiguous amino acids.

Segments of ACT-4 receptor polypeptides are often terminated near boundaries of functional or structural domains. Such segments consist essentially of the amino acids responsible for a particular functional or structural property. Structural and functional domains are identified by comparison of nucleotide and/or amino acid sequence data such as is shown in Fig. 5 to public or proprietary sequence databases. Preferably, computerized comparison methods are used to identify sequence motifs or predicted protein conformation domains that occur in other proteins of known structure and/or function. Structural domains include an intracellular domain, transmembrane domain, and extracellular domain, which is in turn contains three disulfide-bonded loops. Functional domains include an extracellular binding domain through which the ACT-4 receptor polypeptide interacts with external soluble molecules or other cell-bound ligands and an intracellular signal-transducing domain.

Some fragments will contain only extracellular domains, such as one or more disulfide-bonded loops. Such fragments will often retain the binding specificity

29

of an intact ACT-4 receptor polypeptide, but will be soluble rather than membrane bound. Such fragments are useful as competitive inhibitors of ACT-4 receptor binding.

5 ACT-4 receptors are further identified by their status as members of the nerve growth factor receptor family. The amino acid sequence of ACT-4-h-1 is at least 20% identical to NGF-R, TNF-R, CD40, 4-LBB, and fas/APO1. ACT-4-h-1 exhibits 62% amino acid sequence identity with 10 the rat OX-40 gene, which is also characterized by selective expression on activated CD4⁺ cells.

ACT-4 receptors are also identified by a characteristic cellular distribution. Most notably, ACT-4 receptors are usually easily detected on activated CD4⁺ 15 T cells (percent cells expressing usually greater than about 25 or 50% and often about 80%; mean channel fluorescence usually greater than about 10 and often about 20-25, on a Coulter Profile Flow Cytometer after immunofluorescence staining). ACT-4 receptors are usually substantially absent on resting T-cells, B-cells (unless activated with PMA), NK cells, and monocytes (unless activated with PMA). Substantially absent means that the percentage of cells expressing ACT-4 is usually less than about 5%, and more usually less than about 2%, 20 and that the mean channel is usually less than about 4, and more usually less than about 2, measured on a Coulter Profile Flow Cytometer, after immunofluorescence staining of the cells. (See Example 2) ACT-4 receptors are

30

usually expressed at low levels on activated CD8⁺ cells (percent cells expressing about 4-10%; mean channel fluorescence about 2-4 on a Coulter Profile Flow Cytometer after immunofluorescence staining). The low level of expression observed on CD8⁺ cells suggests that expression is confined to a subpopulation of CD8⁺ cells. The expression of ACT-4 receptors on the surface of activated CD4⁺ cells has been observed for several different mechanisms of activation, including alloantigenic, tecanus toxoid or mitogenic (e.g., PHA) stimuli. Expression peaks after about 7 days of allogantigenic or tecanus toxoid stimulation and after about three days of PHA stimulation. These data indicate that ACT-4 receptors should be classified as early activation antigens that are substantially absent on resting cells. The observation that ACT-4 receptors are preferentially expressed on activated CD4⁺ cells and are expressed to a much lesser extent on activated CD8⁺ cells, but are substantially absent on most or all other subtypes of lymphoid cells (except in response to highly nonphysiological stimuli such as PMA) contrasts with the cell type specificity of other activation antigens found on human leukocytes.

The expression of ACT-4 receptors on the surface of activated CD4⁺ T cells suggests that the receptor has a role in activation of these cells. Such a role is consistent with that of some other members of the nerve growth factor receptor family. For example, CD40

25

31

stimulates the G1-S phase transition in B lymphocytes, and nerve growth factor receptor transduces a signal from the cytokine nerve growth factor, which results in neuronal differentiation and survival (Barde, Neuron 2:155-1534 (1989)) (incorporated by reference for all purposes). However, other roles for ACT-4 receptors can also be envisaged, for example, interaction with other lymphoid cell types. The existence of such roles is consistent with the diverse functions of other nerve growth factor receptor family members, such as tumor necrosis factor, whose interaction with tumor necrosis factor receptor can result in inflammation or tumor cell death.

Fragments or analogs comprising substantially one or more functional domain (e.g., an extracellular domain) of ACT-4 receptors can be fused to heterologous polypeptide sequences, such that the resultant fusion protein exhibits the functional property(ies) conferred by the ACT-4 receptor fragment and/or the fusion partner. The orientation of the ACT-4 receptor fragment relative to the fusion partner will depend on experimental considerations such as ease of construction, stability to proteolysis, thermal stability, immunological reactivity, amino- or carboxyl-terminal residue modification, and so forth. Potential fusion partners include chromogenic enzymes such as β -galactosidase, protein A or G, a FLAG protein such as described by Blanar & Rutter, Science 256:1014-1018 (1992), toxins (e.g., diphtheria toxin,

32

Pseudomonas exotoxin A, ricin toxin or phospholipase C) and immunoglobulin components.

Recombinant globulins (Rg) formed by fusion of ACT-4 receptor fragments and immunoglobulin components often have most or all of the physiological properties associated with the constant region of the particular immunoglobulin class used. For example, the recombinant globulins may be capable of fixing complement, mediating antibody dependent cell toxicity, stimulating B cells, or traversing blood vessel walls and entering the interstitial space. The recombinant globulins are usually formed by fusing the C-terminus of an ACT-4 receptor extracellular domain to the N-terminus of the constant region domain of a heavy chain immunoglobulin, thereby simulating the conformation of an authentic immunoglobulin chain. The immunoglobulin chain is preferably of human origin, particularly if the recombinant globulin is intended for therapeutic use. Recombinant globulins are usually soluble and have a number of advantageous properties relative to unmodified ACT-4 receptors. These properties include prolonged serum half-life, the capacity to lyse target cells for which an ACT-4 receptor has affinity, by effector functions, and the capacity to bind molecules such as protein A and G, which can be used to immobilize the recombinant globulin in binding analyses.

II. Ligands to ACT-4

The invention also provides ligands that specifically bind to an ACT-4 receptor polypeptide and that are capable of forming a complex with such a polypeptide, at least in part, by noncovalent binding.

5 The term ACT-4-L ligand polypeptide is used generically to encompass full-length proteins and fragments thereof. This term does not usually include antibodies to ACT-4 receptor polypeptides. The term ACT-4 ligand is usually used to refer to a full-length protein. Ligands can be naturally-occurring or synthetic molecules, and can be in soluble form or anchored to the surface of a cell.

10 Multiple different ligands may bind the same ACT-4 receptor. Conversely, one ligand may bind to more than one ACT-4 receptor. Usually, binding of a ligand to an ACT-4 receptor will initiate a signal that alters the physical and/or functional phenotype of a cell bearing the ACT-4 receptor and/or a cell bearing the ACT-4 ligand. Antibodies against either ACT-4 or its ligands can have the capacity to block or stimulate signal transduction. It will, of course, be recognized that the designation of ACT-4 as a receptor and its specific binding partner(s) as ligand(s) is somewhat arbitrary and might, in some circumstances, be reversed.

15 Source materials for supplying ACT-4-L ligand polypeptides are identified by screening different cell types, particularly lymphoid and hematopoietic cells, bodily fluids and tissue extracts, with labelled ACT-4 receptor polypeptides, preferably in aqueous-soluble

form, as a probe. Activated B cells or B cell lines may be suitable (see Example 8). HTLV-I infected T-cells are also suitable. Often, the ACT-4 receptor or a binding fragment thereof is fused or otherwise linked to a second protein for purposes of screening. Particularly suitable are recombinant globulins formed by fusing the extracellular portion of ACT-4-h-1 to the constant region of an immunoglobulin heavy chain.

5 ACT-4-L ligand polypeptides are purified from cells or other biological materials identified by this screening method using techniques of classical protein chemistry. Such techniques include selective precipitation with such substances as ammonium sulfate, column chromatography, immunopurification methods, and others. See, e.g., R. Scopes, *Protein Purification: Principles and Practice* (Springer-Verlag, NY, 1982) (incorporated by reference for all purposes).

10 Usually, purification procedures will include an affinity chromatography step in which an ACT-4 receptor polypeptide or a binding fragment thereof is used as the immobilized reagent. ACT-4-constant regions can be conveniently immobilized by binding of the constant region moiety to protein A or G. ACT-4-L ligand polypeptides can also be purified using anti-idiotypic antibodies to ACT-4 receptors as the affinity reagent.

15 To determine the amino acid sequence or to obtain polypeptide fragments of a ligand, the ligand can be digested with trypsin. Peptide fragments can be separated by reverse-phase high-performance liquid

35

chromatography (HPLC), and analyzed by gas-phase sequencing. Other sequencing methods known in the art may also be used. The sequence data can be used to design degenerate probes for isolation of cDNA or genomic clones encoding ACT-4-L ligand polypeptides.

Alternatively, cDNA clones encoding ACT-4-L ligand polypeptides can be obtained by expression cloning. In this approach, a cDNA library is prepared from cells expressing an ACT-4-L ligand polypeptides (identified as discussed, *supra*). The library is expressed in appropriate cells (e.g., COS-7), and clones bearing the ACT-4-L ligand polypeptide are identified by screening with labelled ACT-4 or binding fragment thereof, optionally fused to a constant domain of an immunoglobulin heavy chain.

The cDNA sequence and predicted amino acid sequence of the first ligand to an ACT-4 receptor polypeptide to be characterized are shown in Fig. 10. This ligand is designated ACT-4-L-h-1 with the suffix h designating human origin, and the suffix 1 indicating that this is the first ligand to be characterized. The coding portion of the cDNA sequence of ACT-4-L-h-1 is identical or nearly identical to that of a polypeptide termed gp34 or TAA4. See Miura et al., *Mol. Cell. Biol.* 11:1313-1325 (1991) (incorporated by reference in its entirety for all purposes). The invention also includes ligands representing allelic, nonallelic, splice and higher cognate variants of ACT-4-L-h-1, and natural or

36

induced mutants of any of these. Such variants will typically show substantial sequence identity with the ACT-4-L-h-1 sequence, and contain at least 4 and more commonly 5, 6, 7, 10 or 20, 50 or more contiguous amino acids from the ACT-4-L-h-1 sequence. Such variants will also typically be encoded by nucleotide sequences that exhibit substantial sequence identity with the nucleotide sequence encoding ACT-4-L-h-1 shown in Fig. 10. The nucleotides encoding such variants will also typically hybridize to an ACT-4-L-h-1 DNA sequence under stringent conditions. However, some such nucleotides will not hybridize under stringent conditions to DNA sequences encoding lower cognate variants (e.g., rat) of ACT-4-L-h-1. Many variants of ACT-4-L-h-1 will share at least one antigenic determinant with an ACT-4-L-h-1 ligand polypeptide as evidenced by crossreactivity with monoclonal or polyclonal antibodies against the same. However, some such variants will not crossreact with sera against lower cognate variants of ACT-4-L-h-1.

Although many ACT-4-L ligand polypeptides will show similarity to ACT-4-L-h-1 in at least one of the respects discussed above, it is entirely possible that other families of ligands exists to the ACT-4 receptor that show nothing in common with ACT-4-L-h-1 except for the capacity to specifically bind to an ACT-4 receptor. Such families of ligands are expressly included in the invention.

Often ACT-4-L ligand polypeptides will contain

modifications of their backbones of the types discussed in Section I, supra. The ACT-4-L-h-1 polypeptide, for example, is heavily modified in that the observed molecular weight is about 34 kDa, whereas the predicted molecular weight based on amino acid sequence is only 21 kDa. Four putative N-linked glycosylation sites have been identified in the extracellular domain.

Many ACT-4-L ligand polypeptides likely share some or all of the topological features found for ACT-4-L-h-1. The ACT-4-L-h-1 amino acid sequence contains a putative N-terminal intracellular domain (aa 1-23), a putative hydrophobic transmembrane domain (aa 24-50) and a putative extracellular C-terminal domain (aa 51-183). This structural arrangement is consistent with ACT-4-L-h-1 being a type II integral membrane protein (i.e., having a single transmembrane domain with the C-terminal domain comprising the extracellular region and the N-terminus comprising the intracellular region).

ACT-4-L ligand polypeptides may also share some of the structural and/or functional characteristics of ligands that binds to other members of the nerve growth factor receptor superfamily. Such ligands include TNF- α , TNF- β , CD40-L, CD27-L, CD30-L. Although ACT-4-L-h-1 shows only weak primary amino acid sequence identity with TNF- α and even less similarity with other superfamily ligands, a greater similarity between all of these ligands is apparent in their predicted capacity to form higher order structures. The extracellular domains of

known superfamily ligands consist of about 150 amino acids and form several β -pleated sheets, which assemble into a slitted cylindrical structure (termed a "jelly roll" by Bazan et al., Current Biology 3:603-606 (1993)) (incorporated by reference for all purposes). The

extracellular domain of ACT-4-L-h-1 consists of 133 amino acids, and the predicted folding pattern is consistent with the formation of β -pleated sheets and a "jelly roll." Notably, all of the superfamily ligands except TNF- β also exist, in part, as type II integral membrane cell surface proteins. Superfamily ligands also exists as soluble proteins suggesting that such forms exist for ACT-4-L ligand polypeptides. The C-terminal extracellular domain of ACT-4-L-h-1 shows some sequence similarity with various dehydrogenases. Thus, some ACT-4-L ligand polypeptide may possess a dehydrogenase activity, which may play a role in intercellular signalling.

Besides substantially full-length polypeptides, the present invention provides for biologically active fragments of full-length ACT-4-L ligand polypeptides. Significant biological activities include binding to an ACT-4 receptor such as ACT-4-h-1, binding to a second ACT-4-L ligand polypeptide, antibody binding (e.g., the fragment competes with an intact ACT-4-L-h-1 ligand polypeptide for specific binding to an antibody), immunogenicity (i.e., possession of epitopes that stimulate B or T cell responses against the fragment),

39

and agonism or antagonism of the binding of a second ACT-4-L ligand polypeptide to an ACT-4 receptor polypeptide, such as ACT-4-h-1. A segment of a full-length ACT-4-L ligand polypeptide will ordinarily comprise at least 5 contiguous amino acids, but not more than 160 contiguous amino acids from the amino acid sequence shown in Fig. 10. Often segments contain about 10, 20, 50, 75, 100 or 133 amino acids, and not more than 150 contiguous amino acids, from the sequence shown in Fig. 10.

Some fragments will contain only extracellular domains. Such fragments contain the full-length domains of naturally occurring ACT-4-L ligand polypeptides. Other fragments contain components thereof. Such fragments will often retain the binding specificity of an intact ACT-4-L ligand polypeptide, but will be soluble rather than membrane bound. Such fragments are useful as competitive inhibitors of ACT-4-L ligand polypeptide binding to a receptor.

Fragments of full-length ACT-4-L ligand polypeptides are often terminated at one or both of their ends near (i.e., within about 5, 10 or 20 aa of) the boundaries of functional or structural domains. Fragments terminated at both ends by structural or functional boundaries consist essentially of a particular segment (or domain) of ACT-4-L amino acids responsible for a functional or structural property. Structural and functional domains are identified by comparison of nucleotide and/or amino acid sequence data such as is

40

shown in Fig. 10 to public or proprietary sequence databases. Preferably, computerized comparison methods are used to identify sequence motifs or predicted protein conformation domains that occur in other proteins of known structure and/or function. Binding domains can be identified by epitope mapping. See Section VI, infra. Structural domains include an intracellular domain, transmembrane domain, and extracellular domain. Functional domains include an extracellular binding domain through which ACT-4-L ligand polypeptides interact with external soluble molecules or cell-bound receptors and an intracellular signal-transducing domain. Expression of ACT-4-L-h-1 and related ligands is dependent on cell type and activation status. See Example 8. Most notably, ACT-4-L-h-1 is easily detected on some PMA/ionomycin-activated B cell lines. ACT-4-L-h-1 is substantially absent on fresh resting B cells. ACT-4-L-h-1 is also expressed on HLRV-1-infected T-cells and may be infect on other T-cell types in some circumstances. See Example 8.

The affinity of an ACT-4-L ligand (expressed on activated B cells) for an ACT-4 receptor (expressed predominantly on activated CD4⁺ cells) suggests that the interaction between ligand and receptor may have a role in activation/differentiation of CD4⁺ T-cells and/or B cells. Both CD4⁺ T-cell and B-cell activation are known to be multistep processes requiring antigen-specific and nonspecific stimuli. The interaction between ACT-4 and

ACT-4-L would likely constitute a nonantigen-specific stimulus effective on either or both of the respective cells bearing these antigens. The stimulus might be direct when as, for example, the ligand-receptor binding triggers an enzymic activity in the intracellular domain in ligand and/or receptor, which activity in turn initiates a cascade of metabolic events in one or both of the respective cells. Alternatively, the stimulus might be indirect; for example, the interaction between ACT-4 and ACT-4-L might increase the avidity of cellular interactions between other ligand-receptor pairs or control leukocyte localization and migration.

Interaction of ACT-4 and ACT-4-L may act in conjunction with binding of other T_H-B cell receptor/ligand pairs such as CD2/LFA-3 (Mongeon et al., *Nature* 339:314 (1988)), CD4/MHC class II (Doyle & Steminger, *Nature* 330:256-259 (1987), LFA-1/ICAM-1/ICAM-2 (Makgoba et al., *Nature* 331:65-68 (1988) and Staunton et al., *Nature* 339:61-64 (1989)) and B7/CD28 (Linsley et al., *J. Exp. Med.* 173:721-730 (1991)). ACT-4/ACT-4-L interactions may also be enhanced or diminished by binding of soluble molecules to CD4⁺ T-cells and/or B cells. Likely soluble molecules are cytokines including, e.g., interleukins IL-1 through IL-13, tumor necrosis factors α & β , interferons α , β and γ , tumor growth factor Beta (TGF- β), colony stimulating factor (CSF) and granulocyte monocyte colony stimulating factor (GM-CSF).

Expression of ACT-4-L ligand on certain

subtypes of T-cells in some circumstances may confer additional or alternate roles for ACT-4/ACT-4-L interactions. For instance, efficiency of infection of T-cells by human immunodeficiency virus (HIV) or other viruses and pathogens may be affected by ACT-4 or ACT-4-L or by interactions between the two. In addition it is possible that ACT-4 and ACT-4-L could be expressed by the same cells (e.g., activated CD4⁺ T-cells). In these circumstances, interactions between receptor and ligand may affect the growth and activation state of their respective cells.

Fragments or analogs comprising substantially one or more functional domain (e.g., an extracellular domain) of ACT-4-L ligand polypeptides can be fused or otherwise linked to heterologous polypeptide sequences, such that the resultant fusion protein exhibits the functional property(ies) conferred by the ACT-4-L ligand polypeptide and/or the fusion partner. Suitable fusion partners are as discussed in Section I, *supra*.

The ACT-4-L ligand polypeptides can be used to affinity purify respective ACT-4 receptors. ACT-4-L ligand polypeptides are also useful as agonists or antagonists of a second ACT-4-L ligand or an ACT-4 receptor, and can be used in the therapeutic methods discussed in Section VII, *infra*. ACT-4 ligand polypeptides are also useful in screening assays for identifying agonists and antagonists of ACT-4 and/or ACT-4-L.

III. Methods of producing polypeptides

A. Recombinant Technologies

The nucleotide and amino acid sequences of ACT-4-h-1 shown in Fig. 5, and corresponding sequences for other ACT-4 receptor variants allow production of polypeptides of full-length ACT-4 receptor polypeptides sequences and fragments thereof. Similarly, the amino acid sequence of ACT-4-L-h-1 and corresponding sequences for other ACT-4-L ligand polypeptide variants allow production of full-length and fragment ligand polypeptides. Such polypeptides may be produced in prokaryotic or eukaryotic host cells by expression of polynucleotides encoding ACT-4 or ACT-4-L, or fragments and analogs of either of these. The cloned DNA sequences are expressed in hosts after the sequences have been operably linked to (i.e., positioned to ensure the functioning of) an expression control sequence in an expression vector. Expression vectors are typically replicable in the host organisms either as episomes or as an integral part of the host chromosomal DNA. Commonly, expression vectors will contain selection markers, e.g., tetracycline resistance or hygromycin resistance, to permit detection and/or selection of those cells transformed with the desired DNA sequences (see, e.g., U.S. Patent 4,704,362).

E. coli is one prokaryotic host useful for cloning the DNA sequences of the present invention. Other microbial hosts suitable for use include bacilli,

such as *Bacillus subtilis*, and other Enterobacteriaceae, such as *Salmonella*, *Serratia*, and various *Pseudomonas* species. In these prokaryotic hosts, one can also make expression vectors, which will typically contain expression control sequences compatible with the host cell (e.g., an origin of replication). In addition, any number of a variety of well-known promoters will be present, such as the lacrose promoter system, a tryptophan (trp) promoter system, a beta-lactamase promoter system, or a promoter system from phage lambda. The promoters will typically control expression, optionally with an operator sequence, and have ribosome binding site sequences and the like, for initiating and completing transcription and translation.

Other microbes, such as yeast, may also be used for expression. *Saccharomyces* is a preferred host, with suitable vectors having expression control sequences, such as promoters, including 3-phosphoglycerate kinase or other glycolytic enzymes, and an origin of replication, termination sequences and the like as desired. Insect cells (e.g., SF9) with appropriate vectors, usually derived from baculovirus, are also suitable for expressing ACT-4 receptor or ligand polypeptides. See Luckow, et al. *Bio/Technology* 6:7-55 (1988) (incorporated by reference for all purposes).

Higher eukaryotic mammalian tissue cell culture may also be used to express and produce the polypeptides of the present invention (see Winnacker, *Fran Genes* to

Clones (VCH Publishers, NY, NY, 1987)) (incorporated by reference for all purposes). Eukaryotic cells are actually preferred, because a number of suitable host cell lines capable of secreting and authentically modifying human proteins have been developed in the art, and include the CHO cell lines, various COS cell lines, HeLa cells, myeloma cell lines, Jurkat cells, etc. Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter (e.g., a HSV tk promoter or pgk (phosphoglycerate kinase) promoter), an enhancer (Queen et al., *Immunol. Rev.* 89:49 (1986)), and necessary processing information sites, such as ribosome binding sites, RNA splice sites, Polyadenylation sites (e.g., an SV40 large T Ag poly A addition site), and transcriptional terminator sequences. Preferred expression control sequences are promoters derived from immunoglobulin genes, SV40, adenovirus, bovine papillomavirus, and the like. The vectors containing the DNA segments of interest (e.g., polypeptides encoding an ACT-4 receptor) can be transferred into the host cell by well-known methods, which vary depending on the type of cellular host. For example, CaCl₂ transfection is commonly utilized for prokaryotic cells, whereas CaPO₄ treatment or electroporation may be used for other cellular hosts. Vectors may exist as episome or integrated into the host chromosome.

B. Naturally Occurring ACT-4 or ACT-4-L Polypeptides

Natural ACT-4 receptor polypeptides are isolated by conventional techniques such as affinity chromatography. For example, polyclonal or monoclonal antibodies are raised against previously-purified ACT-4-h-1 and attached to a suitable affinity column by well known techniques. See, e.g., Hudson & Hay, *Practical Immunology* (Blackwell Scientific Publications, Oxford, UK, 1990), Chapter 8 (incorporated by reference for all purposes). For example, anti-ACT-4-h-1 can be immobilized to a protein-A sepharose column via crosslinking of the Fc domain with a homobifunctional crosslinking agent, such as dimethyl pimelimidate. Cell extracts are then passed through the column, and ACT-4 receptor protein specifically bound by the column, eluted with, for example, 0.5 M pyrogenic acid, pH 2.5. Usually, an intact form of ACT-4 receptor is obtained by such isolation techniques. Peptide fragments are generated from intact ACT-4 receptors by chemical (e.g., cyanogen bromide) or enzymatic cleavage (e.g., V8 protease or trypsin) of the intact molecule.

Naturally occurring ACT-4-L ligand polypeptides can be purified using an analogous approach except that the affinity reagent is an antibody specific for ACT-4-L-h-1.

C. Other Methods

Alternatively, ACT-4 or ACT-4-L polypeptides can be synthesized by chemical methods or produced by in vitro translation systems using a polynucleotide template to direct translation. Methods for chemical synthesis of polypeptides and in vitro translation are well known in the art, and are described further by Berger & Kimmel, *Methods in Enzymology*, Volume 152, Guide to Molecular Cloning Techniques Academic Press, Inc., San Diego, CA, 1987).

TY Nucleic acids

A Chinese Text as a Model 111

Example 5 presents nucleic acid sequence data for a cDNA clone of an ACT-4 receptor designated ACT-4-h-1. The sequence includes both a translated region and 3' and 5' flanking regions. This sequence data can be used to design probes with which to isolate other ACT-4 receptor genes. These genes include the human genomic gene encoding ACT-4-h-1, and cDNAs and genomic clones from higher mammalian species, and allelic and nonallelic variants, and natural and induced mutants of all of these genes. Specifically, all nucleic acid fragments encoding all ACT-4 receptor polypeptides disclosed in this application are provided. Genomic libraries of many species are commercially available (e.g., Clontech, Palo Alto, CA), or can be isolated de novo by conventional procedures. cDNA libraries are best prepared from

activated CD4⁺ cells, which express ACT-4-h-1 in large amounts.

The probes used for isolating clones typically comprise a sequence of about at least 24 contiguous nucleotides (or their complement) of the cDNA sequence shown in Fig. 5. For example, a full-length polynucleotide corresponding to the sequence shown in Fig. 5 can be labeled and used as a hybridization probe to isolate genomic clones from a human genomic clone library in e.g., λEMBL4 or λGEM11 (Promega Corporation, Madison, WI); typical hybridization conditions for screening plaque lifts (Benton & Davis, Science 196:180 (1978)) can be: 50% formamide, 5 x SSC or SSPE, 1-5 x Denhardt's solution, 0.1-1% SDS, 100-200 µg sheared heterologous DNA or tRNA, 0-10⁴ dextran sulfate, 1 x 10⁴ to 1 x 10⁵ cpm/ml of denatured probe with a specific activity of about 1 x 10⁸ cpm/µg, and incubation at 42°C for about 6-36 hours. Prehybridization conditions are essentially identical except that probe is not included and incubation time is typically reduced. Washing conditions are typically 1-3 x SSC, 0.1-1% SDS, 50-70°C with change of wash solution at about 5-30 minutes. Hybridization and washing conditions are typically less stringent for isolation of higher cognate or nonallelic variants than for e.g., the human genomic clone of ACT-4-
h-1.

Alternatively, probes can be used to clone ACT-4-
4 receptor genes by methods employing the polymerase

chain reaction (PCR). Methods for PCR amplification are described in e.g., *PCR Technology: Principles and Applications for DNA Amplification* (ed. H.A. Erlich, Freeman Press, NY, 1992); *PCR Protocols: A Guide to Methods and Applications* (eds. Innis, et al., Academic Press, San Diego, CA, 1990); Mattila, et al., *Nucleic Acids Res.* 19:4967 (1991); Eckert, K.A. and Kunzel, T.A., *PCR Methods and Applications* 1:17 (1991); PCR (eds. McPherson et al., IRL Press, Oxford); and U.S. Patent 4,683,202 (each of which is incorporated by reference for all purposes).

Alternatively, synthetic polynucleotide sequences corresponding to all or part of the sequences shown in Fig. 5 may be constructed by chemical synthesis of oligonucleotides. Nucleotide substitutions, deletions, and additions can be incorporated into the polynucleotides of the invention. Nucleotide sequence variation may result from degeneracy of the genetic code, from sequence polymorphisms of various ACT-4 receptor alleles, minor sequencing errors, or may be introduced by random mutagenesis of the encoding nucleic acids using irradiation or exposure to EMS, or by changes engineered by site-specific mutagenesis or other techniques of modern molecular biology. See Sambrook et al., *Molecular Cloning: A Laboratory Manual* (C.S.H.P. Press, NY 2d ed., 1989) (incorporated by reference for all purposes). For nucleotide sequence that are capable of being transcribed and translated to produce a functional polypeptide,

degeneracy of the genetic code results in a number of nucleotide sequences that encode the same polypeptide. The invention includes all such sequences. Generally, nucleotide substitutions, deletions, and additions should not substantially disrupt the ability of an ACT-4 receptor polynucleotide to hybridize to the sequence of ACT-4-h-1 shown in Fig. 5 under stringent conditions. Typically, ACT-4 receptor polynucleotides comprise at least 25 consecutive nucleotides which are substantially identical to a naturally-occurring ACT-4 receptor sequence (e.g., Fig. 5), more usually ACT-4 receptor polynucleotides comprise at least 50 to 100 consecutive nucleotides, which are substantially identical to a naturally-occurring ACT-4 receptor sequence.

ACT-4 receptor polynucleotides can be short oligonucleotides (e.g., about 10, 15, 25, 50 or 100 contiguous bases from the ACT-h-1 sequence shown in Fig. 5), such as for use as hybridization probes and PCR (or LCR) primers. ACT-4 receptor polynucleotide sequences can also comprise part of a larger polynucleotide that includes sequences that facilitate transcription (expression sequences) and translation of the coding sequences, such that the encoded polypeptide product is produced. Construction of such polynucleotides is well known in the art and is described further in Sambrook et al., *supra* (C.S.H.P. Press, NY 2d ed. 1989). The ACT-4 receptor polynucleotide can be fused in frame with another polynucleotide sequence encoding a different

protein (e.g., glutathione S-transferase, β -galactosidase or an immunoglobulin Fc domain) for encoding expression of a fusion protein (see, e.g., Byrn et al., *Nature*, 344:667-670 (1990)) (incorporated by reference for all purposes).

5 Nucleic acids encoding ACT-4-L genes can be produced by an analogous approach, using the ACT-4-L-h-1 cDNA sequence shown in Fig. 10 as a starting material for probe design. ACT-4-L genes include the human genomic gene encoding ACT-4-L-h-1, allelic and nonallelic variants, higher cognate variants, and natural and induced mutants of all of these genes. Specifically, all nucleic acid fragments (genomic, cDNA or synthetic) encoding all ACT-4-L polypeptides disclosed in this application are provided. In nucleic acid fragments having mutations of naturally occurring sequences, generally the mutation will not substantially disrupt the ability of an ACT-4-L polynucleotide to hybridize to the nucleotide sequence of ACT-4-L-h-1 under stringent conditions. ACT-4-L ligand polynucleotides can be short oligonucleotides (e.g., about 10, 15, 25, 50 or 100 contiguous bases from the ACT-4-L-h-1 sequence shown in Fig. 10), such as for use as hybridization probes and PCR (or LCR) primers. ACT-4-L ligand polynucleotide sequences can also comprise part of a larger polynucleotide as discussed in connection with ACT-4 polynucleotide sequences.

5

A. General Characteristics of Antibodies

Antibodies or immunoglobulins are typically composed of four covalently bound peptide chains. For example, an IgG antibody has two light chains and two heavy chains. Each light chain is covalently bound to a heavy chain. In turn each heavy chain is covalently linked to the other to form a "Y" configuration, also known as an immunoglobulin conformation. Fragments of these molecules, or even heavy or light chains alone, may bind antigen. Antibodies, fragments of antibodies, and individual chains are also referred to herein as immunoglobulins.

A normal antibody heavy or light chain has an N-terminal (NH₂) variable (V) region, and a C-terminal (-COOH) constant (C) region. The heavy chain variable region is referred to as V_H (including, for example, V_L), and the light chain variable region is referred to as V_L (including V_H or V_L). The variable region is the part of the molecule that binds to the antibody's cognate antigen, while the FC region (the second and third domains of the C region) determines the antibody's effector function (e.g., complement fixation, opsonization). Full-length immunoglobulin or antibody

V. Antibodies and Hybridomas
In another embodiment of the invention, antibodies against ACT-4 and ACT-4-L polypeptides are provided.

5

10 Nucleic acids encoding ACT-4-L genes can be produced by an analogous approach, using the ACT-4-L-h-1 cDNA sequence shown in Fig. 10 as a starting material for probe design. ACT-4-L genes include the human genomic gene encoding ACT-4-L-h-1, allelic and nonallelic variants, higher cognate variants, and natural and induced mutants of all of these genes. Specifically, all nucleic acid fragments (genomic, cDNA or synthetic) encoding all ACT-4-L polypeptides disclosed in this application are provided. In nucleic acid fragments having mutations of naturally occurring sequences, generally the mutation will not substantially disrupt the ability of an ACT-4-L polynucleotide to hybridize to the nucleotide sequence of ACT-4-L-h-1 under stringent conditions. ACT-4-L ligand polynucleotides can be short oligonucleotides (e.g., about 10, 15, 25, 50 or 100 contiguous bases from the ACT-4-L-h-1 sequence shown in Fig. 10), such as for use as hybridization probes and PCR (or LCR) primers. ACT-4-L ligand polynucleotide sequences can also comprise part of a larger polynucleotide as discussed in connection with ACT-4 polynucleotide sequences.

5

15 Nucleic acids encoding ACT-4-L genes can be produced by an analogous approach, using the ACT-4-L-h-1 cDNA sequence shown in Fig. 10 as a starting material for probe design. ACT-4-L genes include the human genomic gene encoding ACT-4-L-h-1, allelic and nonallelic variants, higher cognate variants, and natural and induced mutants of all of these genes. Specifically, all nucleic acid fragments (genomic, cDNA or synthetic) encoding all ACT-4-L polypeptides disclosed in this application are provided. In nucleic acid fragments having mutations of naturally occurring sequences, generally the mutation will not substantially disrupt the ability of an ACT-4-L polynucleotide to hybridize to the nucleotide sequence of ACT-4-L-h-1 under stringent conditions. ACT-4-L ligand polynucleotides can be short oligonucleotides (e.g., about 10, 15, 25, 50 or 100 contiguous bases from the ACT-4-L-h-1 sequence shown in Fig. 10), such as for use as hybridization probes and PCR (or LCR) primers. ACT-4-L ligand polynucleotide sequences can also comprise part of a larger polynucleotide as discussed in connection with ACT-4 polynucleotide sequences.

20

20 Nucleic acids encoding ACT-4-L genes can be produced by an analogous approach, using the ACT-4-L-h-1 cDNA sequence shown in Fig. 10 as a starting material for probe design. ACT-4-L genes include the human genomic gene encoding ACT-4-L-h-1, allelic and nonallelic variants, higher cognate variants, and natural and induced mutants of all of these genes. Specifically, all nucleic acid fragments (genomic, cDNA or synthetic) encoding all ACT-4-L polypeptides disclosed in this application are provided. In nucleic acid fragments having mutations of naturally occurring sequences, generally the mutation will not substantially disrupt the ability of an ACT-4-L polynucleotide to hybridize to the nucleotide sequence of ACT-4-L-h-1 under stringent conditions. ACT-4-L ligand polynucleotides can be short oligonucleotides (e.g., about 10, 15, 25, 50 or 100 contiguous bases from the ACT-4-L-h-1 sequence shown in Fig. 10), such as for use as hybridization probes and PCR (or LCR) primers. ACT-4-L ligand polynucleotide sequences can also comprise part of a larger polynucleotide as discussed in connection with ACT-4 polynucleotide sequences.

25

25 Nucleic acids encoding ACT-4-L genes can be produced by an analogous approach, using the ACT-4-L-h-1 cDNA sequence shown in Fig. 10 as a starting material for probe design. ACT-4-L genes include the human genomic gene encoding ACT-4-L-h-1, allelic and nonallelic variants, higher cognate variants, and natural and induced mutants of all of these genes. Specifically, all nucleic acid fragments (genomic, cDNA or synthetic) encoding all ACT-4-L polypeptides disclosed in this application are provided. In nucleic acid fragments having mutations of naturally occurring sequences, generally the mutation will not substantially disrupt the ability of an ACT-4-L polynucleotide to hybridize to the nucleotide sequence of ACT-4-L-h-1 under stringent conditions. ACT-4-L ligand polynucleotides can be short oligonucleotides (e.g., about 10, 15, 25, 50 or 100 contiguous bases from the ACT-4-L-h-1 sequence shown in Fig. 10), such as for use as hybridization probes and PCR (or LCR) primers. ACT-4-L ligand polynucleotide sequences can also comprise part of a larger polynucleotide as discussed in connection with ACT-4 polynucleotide sequences.

53

"light chains" (generally about 25 kDa, about 214 amino acids) are encoded by a variable region gene at the N-terminus (generally about 110 amino acids), and a κ (kappa) or λ (lambda) constant region gene at the COOH-terminus. Full-length immunoglobulin or antibody "heavy chains" (generally about 50 kDa, about 446 amino acids), are similarly encoded by a variable region gene (generally encoding about 116 amino acids) and one of the constant region genes, e.g., gamma (encoding about 330 amino acids). Typically, the " V_L " will include the portion of the light chain encoded by the V_L and/or J_L (J or joining region) gene segments, and the " V_H " will include the portion of the heavy chain encoded by the V_H , and/or D_H (D or diversity region) and J_H gene segments. See, generally, Roitt et al., *Immunology* (2d ed. 1988), Chapter 6 and Paul, *Fundamental Immunology* (Raven Press, 2d ed., 1989) (each of which is incorporated by reference for all purposes).

An immunoglobulin light or heavy chain variable region consists of a "framework" region interrupted by three hypervariable regions, also called complementarity-determining regions or CDRs. The extent of the framework region and CDRs have been defined (see Rabat et al. (1987), "Sequences of Proteins of Immunological Interest," U.S. Department of Health and Human Services; Chothia et al., *J. Mol. Biol.* 196:901-917 (1987) (each of which is incorporated by reference for all purposes)). The sequences of the framework regions of different light

54

or heavy chains are relatively conserved within a species. The framework region of an antibody, that is the combined framework regions of the constituent light and heavy chains, serves to position and align the CDRs in three dimensional space. The CDRs are primarily responsible for binding to an epitope of an antigen. The CDRs are typically referred to as CDR1, CDR2, and CDR3, numbered sequentially starting from the N-terminus.

The constant region of the heavy chain molecule, also known as C_H , determines the isotype of the antibody. Antibodies are referred to as IgM, IgD, IgG, IgA, and IgE depending on the heavy chain isotype. The isotypes are encoded in the mu (μ), delta (δ), gamma (γ), alpha (α), and epsilon (ϵ) segments of the heavy chain constant region, respectively. In addition, there are a number of γ subtypes. There are two types of light chains, κ and λ . The determinants of these subtypes typically reside in the constant region of the light chain, also referred to as the C_L in general, and C_{κ} or C_{λ} , in particular.

The heavy chain isotypes determine different effector functions of the antibody, such as opsonization or complement fixation. In addition, the heavy chain isotype determines the secreted form of the antibody. Secreted IgG, IgD, and IgE isotypes are typically found in single unit or monomeric form. Secreted IgM isotype is found in pentameric form; secreted IgA can be found in both monomeric and dimeric form.

55
B. Production of Antibodies

Antibodies which bind either an ACT-4 receptor, an ACT-4-L ligand, or binding fragments of either, can be produced by a variety of means. The production of non-human monoclonal antibodies, e.g., murine, rat and so forth, is well known and may be accomplished by, for example, immunizing the animal with a preparation containing an ACT-4 receptor or its ligands, or an immunogenic fragment of either of these. Particularly, useful as immunogens are cells stably transfected with a recombinant ACT-4 or ACT-4-L gene and expressing an ACT-4 receptor or ligand thereto on their cell surface.

Antibody-producing cells obtained from the immunized animals are immortalized and screened for the production of an antibody which binds to ACT-4 receptors or their ligands. See Harlow & Lane, *Antibodies, A Laboratory Manual* (C.S.H.P. NY, 1988) (incorporated by reference for all purposes). A number of murine antibodies to a protein having a substantially similar or identical primary amino acid sequence to ACT-4-L-h-1 have been discussed by Tozawa et al., *Int. J. Cancer* 41:331-338 (1988); Tanaka et al., *Int. J. Cancer* 36:549-555 (1985) (incorporated by reference in their entirety for all purposes).

Several techniques for generation of human monoclonal antibodies have also been described but are generally more onerous than murine techniques and not applicable to all antigens. See, e.g., Larrick et al.,

56

U.S. Patent No. 5,001,065, for review (incorporated by reference for all purposes). One technique that has successfully been used to generate human monoclonal antibodies against a variety of antigens is the trioma methodology of Ostberg et al. (1983), Hybridoma 2:361-367, Ostberg, U.S. Patent No. 4,634,664, and Engleman et al., US Patent 4,634,666 (incorporated by reference for all purposes). The antibody-producing cell lines obtained by this method are called triomas, because they are descended from three cells--two human and one mouse. Triomas have been found to produce antibody more stably than ordinary hybridomas made from human cells.

An alternative approach is the generation of humanized immunoglobulins by linking the CDR regions of non-human antibodies to human constant regions by recombinant DNA techniques. See Queen et al., *Proc. Natl. Acad. Sci. USA* 86:10029-10033 (1989) and WO 90/07861 (incorporated by reference for all purposes). The humanized immunoglobulins have variable region framework residues substantially from a human immunoglobulin (termed an acceptor immunoglobulin) and complementarity determining regions substantially from a mouse immunoglobulin, e.g., the L106 antibody (see Example 1) (referred to as the donor immunoglobulin).

The constant region(s), if present, are also substantially from a human immunoglobulin. The human variable domains are usually chosen from human antibodies whose framework sequences exhibit a high degree of

sequence identity with the murine variable region domains from which the CDRs were derived. The heavy and light chain variable region framework residues can be derived from the same or different human antibody sequences. The human antibody sequences can be the sequences of naturally occurring human antibodies or can be consensus sequences of several human antibodies. See Carter et al., WO 92/22653. Certain amino acids from the human variable region framework residues are selected for substitution based on their possible influence on CDR conformation and/or binding to antigen. Investigation of such possible influences is by modeling, examination of the characteristics of the amino acids at particular locations, or empirical observation of the effects of substitution or mutagenesis of particular amino acids.

For example, when an amino acid differs between a murine L106 variable region framework residue and a selected human variable region framework residue, the human framework amino acid should usually be substituted by the equivalent framework amino acid from the mouse antibody when it is reasonably expected that the amino acid:

- (1) noncovalently binds antigen directly,
- (2) is adjacent to a CDR region,
- (3) otherwise interacts with a CDR region (e.g., is within about 3 Å of a CDR region), or
- (4) participates in the V_l-V_h interface.

Other candidates for substitution are acceptor

human framework amino acids that are unusual for a human immunoglobulin at that position. These amino acids can be substituted with amino acids from the equivalent position of the L106 antibody or from the equivalent positions of more typical human immunoglobulins.

A further approach for isolating DNA sequences which encode a human monoclonal antibody or a binding fragment thereof is by screening a DNA library from human B cells according to the general protocol outlined by Huse et al., Science 246:1275-1281 (1989) and then cloning and amplifying the sequences which encode the antibody (or binding fragment) of the desired specificity. The protocol described by Huse is rendered more efficient in combination with phage display technology. See, e.g., Dower et al., WO 91/17271 and McCafferty et al., WO 92/01047. Phage display technology can also be used to mutagenize CDR regions of antibodies previously shown to have affinity for ACT-4 receptors or their ligands. Antibodies having improved binding affinity are selected.

Anti-ACT-4 receptor antibodies that specifically bind to the same epitope as the L106 antibody are usually identified by a competitive binding assay. The assay has three components, an ACT-4 polypeptide (e.g., ACT-4-h-1), L106 antibody, which is usually labelled, and the antibody under test. Often the ACT-4 receptor polypeptide is immobilized to a solid support. The test antibody binds to the same epitope as

human framework amino acids that are unusual for a human immunoglobulin at that position. These amino acids can be substituted with amino acids from the equivalent position of the L106 antibody or from the equivalent positions of more typical human immunoglobulins.

A further approach for isolating DNA sequences which encode a human monoclonal antibody or a binding fragment thereof is by screening a DNA library from human B cells according to the general protocol outlined by Huse et al., Science 246:1275-1281 (1989) and then cloning and amplifying the sequences which encode the antibody (or binding fragment) of the desired specificity. The protocol described by Huse is rendered more efficient in combination with phage display technology. See, e.g., Dower et al., WO 91/17271 and McCafferty et al., WO 92/01047. Phage display technology can also be used to mutagenize CDR regions of antibodies previously shown to have affinity for ACT-4 receptors or their ligands. Antibodies having improved binding affinity are selected.

Anti-ACT-4 receptor antibodies that specifically bind to the same epitope as the L106 antibody are usually identified by a competitive binding assay. The assay has three components, an ACT-4 polypeptide (e.g., ACT-4-h-1), L106 antibody, which is usually labelled, and the antibody under test. Often the ACT-4 receptor polypeptide is immobilized to a solid support. The test antibody binds to the same epitope as

59

the L106 antibody if it reduces the amount of L106 antibody that specifically binds to the ACT-4 receptor polypeptide. The extent of screening necessary to obtain such antibodies can be reduced by generating antibodies with a protocol in which the specific epitope bound by L106 is used as an immunogen. Antibodies binding to the same epitope as L106 may exhibit a substantially, but not completely, identical amino acid sequence to the L106 antibody, or may have an unrelated primary structure to the L106 antibody.

Anti-ACT-4 receptor antibodies having a different binding specificity than L106 (i.e., which bind to a different epitope) are identified by a complementary approach. Test antibodies are screened for failure to compete with the L106 antibody for binding to an ACT-4 receptor polypeptide. The extent of screening can be reduced by generating antibodies with a protocol in which a fragment lacking a specific epitope bound by L106 is used as an immunogen.

Antibodies having the same or different binding specificity to a selected antibody to an ACT-4-L ligand polypeptide can be identified by analogous procedures.

Antibodies having the capacity to stimulate or inhibit activation of CD4⁺ or B cells can be identified by the screening procedures discussed in Section VI, infra. Some antibodies may selectively inhibit activation in response to some stimuli (e.g., alloantigenic but not mitogenic, or vice versa), and not to others. Some

60

antibodies' inhibitory capacity may depend on the time after activation at which the antibody is added. Some antibodies may have the capacity to activate CD4⁺ or B cells independently of other stimuli, whereas other antibodies may only have the capacity to augment the efficacy of another stimulus such as that provided by PHA or PMA/ionomycin.

Antibodies isolated by the above procedures can be used to generate anti-idiotypic antibodies by, for example, immunization of an animal with the primary antibody. For anti-ACT-4 receptor antibodies, anti-idiotype antibodies whose binding to the primary antibody is inhibited by ACT-4 receptors or fragments thereof are selected. Because both the anti-idiotypic antibody and the ACT-4 receptors or fragments thereof bind the primary immunoglobulin, the anti-idiotypic immunoglobulin may represent the "internal image" of an epitope and thus may substitute for the ACT-4-L ligand polypeptide. Anti-idiotypic antibodies to an ACT-4-L ligand polypeptide that can substitute for an ACT-4 receptor can be produced by an analogous approach.

C. Epitope Mapping

The epitope bound by the L106 antibody or any other selected antibody to an ACT-4 receptor is determined by providing a family of fragments containing different amino acid segments from an ACT-4 receptor polypeptide, such as ACT-4-h-1. Each fragment typically

61

comprises at least 4, 6, 8, 10, 20, 50 or 100 contiguous amino acids. Collectively, the family of polypeptide covers much or all of the amino acid sequence of a full-length ACT-4 receptor polypeptide. Members of the family are tested individually for binding to e.g., the L106 antibody. The smallest fragment that can specifically bind to the antibody under test delineates the amino acid sequence of the epitope recognized by the antibody. An analogous approach is used to map epitopes bound by antibodies to the ACT-4 ligand polypeptides.

D. Fragments of Antibodies, and Immunotoxins

In another embodiment of the invention, fragments of antibodies against ACT-4 receptors or their ligands are provided. Typically, these fragments exhibit specific binding to the ACT-4 receptor or ligand with an affinity of at least 10^7 M, and more typically 10^8 or 10^9 M. Antibody fragments include separate heavy chains, light chains Fab, Fab' F(ab'), Fabc, and Fv. Fragments are produced by recombinant DNA techniques, or by enzymic or chemical separation of intact immunoglobulins. In another embodiment, immunotoxins are provided. An immunotoxin is a chimeric compound consisting of a toxin linked to an antibody having a desired specificity. The antibody serves as a targeting agent for the toxin. See generally Pastan et al., Cell 47:641-648 (1986). A toxin moiety is couple to an intact antibody or a fragment thereof by chemical or recombinant

62

DNA techniques. Preferably, the toxin is linked to an immunoglobulin chain in the form of a contiguous protein. See, e.g., Chovnick et al., Cancer Res. 51:465; Chaudhary et al., Nature 339:394 (1989) (incorporated by reference for all purposes). Examples of suitable toxin components are listed in Section I, *supra*, and are reviewed in, e.g., *The Specificity and Action of Animal, Bacterial and Plant Toxins* (ed. P. Cuatrecasas, Chapman Hall, London, 1976) (incorporated by reference for all purposes).

10

E. Hybridomas and Other Cell Lines

All hybridomas, triomas and other cell lines producing the antibodies and their fragments discussed, supra, are expressly included in the invention. These include the hybridoma line HBBL06, deposited under the Budapest Treaty at the American Type Culture Collection, Rockville, MD 20852 as ATCC HB11483, which produces the L106 mouse antibody.

20

F. Uses of Antibodies

Antibodies to ACT-4 and ACT-4-L polypeptides and their binding fragments are useful for screening cDNA expression libraries, preferably containing human or primate cDNA derived from various tissues and for identifying clones containing cDNA inserts, which encode structurally-related, immunoreactive proteins. See Aruffo & Seed, Proc. Natl. Acad. Sci. USA 84:8573-8577 (1987) (incorporated by reference for all purposes).

63

Antibodies are also useful to identify and/or purify immunoreactive proteins that are structurally or evolutionarily related to the native ACT-4 receptor or ACT-4-L ligand polypeptides or to fragments thereof used to generate the antibody. Diagnostic and therapeutic uses of antibodies, binding fragments thereof, immunotoxins and idiotypic antibodies are described in Section VII, infra.

VI. Screening for Agonists and Antagonists

ACT-4 and ACT-4-L polypeptides, fragments, analogs thereof, antibodies and anti-idiotypic antibodies thereto, as well as other chemical or biological agents are screened for their ability to block or enhance binding of an ACT-4 to its ligand. In addition, they are tested for their ability to stimulate or inhibit metabolic processes, such as DNA synthesis or protein phosphorylation in cells bearing either an ACT-4 receptor or an ACT-4-L ligand polypeptide anchored to their surfaces.

In some methods, the compound under test is screened for its ability to block or enhance binding of a purified binding fragment of an ACT-4 receptor (or fusion protein thereof) to a purified binding fragment of an ACT-4-L ligand polypeptide (or fusion protein thereof). In such experiments, either the receptor or ligand fragment is usually immobilized to a solid support. The test compound then competes with an ACT-4 or ACT-4-L

64

fragment (whichever is not attached to the support) for binding to the support. Usually, either the test compound or the competing ligand or receptor is labelled. In other methods, either or both of the ACT-4 receptor and ACT-4-L ligand polypeptide, or binding fragments of these molecules, are expressed on a cell surface. For example, an ACT-4-L ligand polypeptide may be expressed on activated B-cells and/or an ACT-4 receptor polypeptide expressed on activated CD4+ T-cells.

Alternatively, either the ligand or receptor can be expressed from recombinant DNA in e.g., COS-7 cells (see Example 6). In these methods, the existence of agonism or antagonism is determined from the degree of binding between an ACT-4 receptor and its ligand that occurs in the presence of the test compound. Alternatively, activity of the test compound is assayed by measurement of ³H-thymidine incorporation into DNA or ³⁵P-incorporation into proteins in cells bearing an ACT-4-L receptor and/or cells bearing an ACT-4-L ligand polypeptide.

Compounds that block ACT-4 or ACT-4-L polypeptide-induced DNA synthesis or protein phosphorylation are antagonists. Compounds that activate DNA synthesis or phosphorylation via interaction with an ACT-4 receptor or its ligands are agonists. Agonistic or antagonistic activity can also be determined from other functional or physical endpoints of leukocyte activation, or from clinically desirable or undesirable outcomes,

65

such as cytolytic activity, or extravasation of leukocytes into tissues from blood vessels.

The ability of agents to agonize or antagonize T-cell proliferation *in vitro* can be correlated with the ability to affect the immune response *in vivo*. *In vivo* activity is typically assayed using suitable animal models such as mice or rats. To assay the effect of agents on allograft rejection, for example, potential therapeutic agents can be administered to the animals at various times before introduction of the allogeneic tissue; and the animals can be monitored for graft rejection. Suitable methods for performing the transplant and monitoring for graft rejection have been described (see, e.g., Hsiao et al., *J. Thorac. Cardiovasc. 100:360-370 (1990)* (incorporated by reference for all purposes)).

VII. Therapeutic and Diagnostic Methods and Compositions

A. Diagnostic Methods

Diseases and conditions of the immune system associated with an altered abundance, or functional mutation, of an ACT-4 receptor or its mRNA, or an ACT-4-L ligand or its mRNA may be diagnosed using the probes and/or antibodies of the present invention. Detection of an ACT-4 receptor or mRNA allows activated CD4⁺ T-cells to be distinguished from other leukocyte subtypes. For example, ACT-4 receptor can be detected using an antibody or an ACT-4-L polypeptide that specifically binds to the

66

ACT-4 receptor. The presence of activated CD4⁺ T-cells is indicative of a MHC class II induced immune response against, e.g., invading bacteria. Comparison of the numbers of activated CD4⁺ cells and CD8⁺ cells may allow differential diagnosis between bacterial and viral infections, which predominantly induce these respective activated cell types. The presence of activated CD4⁺ cells is also indicative of undesirable diseases and conditions of the immune system, such as allograft rejection, graft versus host disease, autoimmune diseases, allergies and inflammation. The efficacy of therapeutic agents in treating such diseases and conditions can be monitored.

Detection of ACT-4-L ligand or its mRNA may indicate the presence of activated B-cells and/or signal that the appearance of activated CD4⁺ T-cells is imminent. ACT-4-L ligand can, for example, be detected using an antibody or an ACT-4 receptor polypeptide that specifically binds to the ACT-4-L ligand. Successive detection of ACT-4-L ligand followed by ACT-4 receptor (or vice versa) can allow monitoring of a progression through different temporal stages of activation in an immune response.

Diagnosis can be accomplished by removing a cellular sample (e.g., blood sample, lymph node biopsy or tissue) from a patient. The sample is then subjected to analysis for determining: (1) the amount of expressed ACT-4 receptor or ACT-4-L ligand in individual cells of

67

the sample (e.g., by immunohistochemical staining of fixed cells with an antibody or FACS™ analysis), (2) the amount of ACT-4 receptor or ACT-4-L ligand mRNA in individual cells (by *in situ* hybridization with a labelled complementary polynucleotide probe), (3) the amount of ACT-4 receptor or ACT-4-L ligand mRNA in the cellular sample by RNA extraction followed by hybridization to a labeled complementary polynucleotide probe (e.g., by Northern blotting, dot blotting, solution hybridization or quantitative PCR), or (4) the amount of ACT-4 receptor or ACT-4-L ligand in the cellular sample (e.g., by cell disruption followed by immunoassay or Western blotting of the resultant cell extract).

Diagnosis can also be achieved by *in vivo* administration of a diagnostic reagent (e.g., a labelled anti-ACT-4 or ACT-4-L antibody for monitoring of activated CD4+ T-cells or B-cells, respectively) and detection by *in vivo* imaging. The concentration of diagnostic agent administered should be sufficient that the binding to those cells having the target antigen is detectable compared to the background signal. Further, it is desirable that the diagnostic reagent can be rapidly cleared from the circulatory system in order to give the best target-to-background signal ratio. The diagnostic reagent can be labelled with a radioisotope for camera imaging, or a paramagnetic isotope for magnetic resonance or electron spin resonance imaging. A change (typically an increase) in the level

68

of protein or mRNA of an ACT-4 receptor or ACT-4-L ligand in a cellular sample from an individual, which is outside the range of clinically established normal levels, may indicate the presence of an undesirable immune reaction in the individual from whom the sample was obtained, and/or indicate a predisposition of the individual for developing (or progressing through) such a reaction. Protein or mRNA levels may be employed as a differentiation marker to identify and type cells of certain lineages (e.g., activated CD4+ cells for the ACT-4 receptor) and developmental origins. Such cell-type specific detection may be used for histopathological diagnosis of undesired immune responses.

15

B. Diagnostic Kits

In another aspect of the invention, diagnostic kits are provided for the diagnostic methods described supra. The kits comprise container(s) enclosing the diagnostic reagents, such as labelled antibodies against ACT-4 receptors and ACT-4-L ligands, and reagents and/or apparatus for detecting the label. Other components routinely found in such kits may also be included together with instructions for performing the diagnostic test.

25

69

C. Pharmaceutical Compositions.

The pharmaceutical compositions used for prophylactic or therapeutic treatment comprise an active therapeutic agent, for example, an ACT-4 receptor, an ACT-4-L ligand, fragments thereof, and antibodies and idiotypic antibodies thereto, and a variety of other components. The preferred form depends on the intended mode of administration and therapeutic application. The compositions may also include, depending on the formulation desired, pharmaceutically-acceptable, non-toxic carriers or diluents, which are defined as vehicles commonly used to formulate pharmaceutical compositions for animal or human administration. The diluent is selected so as not to affect the biological activity of the combination. Examples of such diluents are distilled water, physiological saline, Ringer's solutions, dextrose solution, and Hank's solution. In addition, the pharmaceutical composition or formulation may also include other carriers, adjuvants, or nontoxic, nontherapeutic, nonimmunogenic stabilizers and the like.

70

antibodies and anti-idiotypic antibodies thereto, binding fragments of these antibodies, humanized versions of these antibodies, immunotoxins, and other agents discussed, *supra*. Some therapeutic agents function by blocking or otherwise antagonizing the action of an ACT-4 receptor with its ligand. Preferred therapeutic agents compete with the ligand for binding to the receptor, or compete with the receptor for binding to the ligand. Other therapeutic agents function by killing cells bearing a polypeptide against which the agent is targeted. For example, anti-ACT-4 receptor antibodies with effector functions or which are conjugated to toxins, radioisotopes or drugs are capable of selectively killing activated CD4⁺ T-cells. Similarly, anti-ACT-4-L ligand antibodies are capable of killing activated B cells under analogous circumstances. Selective elimination of activated cells is particularly advantageous because an undesirable immune response can be reduced or eliminated, while preserving a residual immune capacity in the form of inactivated B-cells, CD4⁺ cells and CD8⁺ cells to combat invading microorganisms to which a patient may subsequently be exposed. Other therapeutic agents function as agonists of the interaction between an ACT-4 receptor and ACT-4-L ligand.

D. Therapeutic Methods.

The therapeutic methods employ the therapeutic agents discussed above for treatment of various diseases in humans or animals, particularly vertebrate mammals. The therapeutic agents include ACT-4 receptors, binding fragments thereof, ACT-4-L ligands, binding fragments thereof, anti-ACT-4 receptor and anti-ACT-4-L ligand

25

25

71

1. Dosages and Methods of Administration

In therapeutic applications, a pharmaceutical composition (e.g., comprising an antibody to ACT-4-h-1 or ACT-4-L-h-1) is administered, *in vivo* or *ex vivo*, to a patient already suffering from an undesirable immune response (e.g., transplant rejection), in an amount sufficient to cure, partially arrest, or detectably slow the progression of the condition, and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose" or "efficacious dose."

Amounts effective for this use will depend upon the severity of the condition, the general state of the patient, and the route of administration, and combination with other immunosuppressive drugs, if any, but generally range from about 10 ng to about 1 g of active agent per dose, with single dosage units of from 10 mg to 100 mg per patient being commonly used. Pharmaceutical compositions can be administered systemically by intravenous infusion, or locally by injection. The latter is particularly useful for localized undesired immune response such as host *versus* graft rejection. For a brief review of methods for drug delivery, see Langer, *Science* 249:1527-1533 (1990) (incorporated by reference for all purposes).

In prophylactic applications, pharmaceutical compositions are administered to a patients at risk of, but not already suffering an undesired immune reaction (e.g., a patient about to undergo transplant surgery).

72

The amount of agents to be administered is a "prophylactically effective dose," the precise amounts of which will depend upon the patient's state of health and general level of immunity, but generally range from 10 ng to 1 g per dose, especially 10 mg to 100 mg per patient.

Because the therapeutic agents of the invention are likely to be more selective and generally less toxic than conventional immunomodulating agents, they will be less likely to cause the side effects frequently observed with the conventional agents. Moreover, because some of the therapeutic agents are human protein sequences (e.g., binding fragments of an ACT-4 receptor or ACT-4 ligand or humanized antibodies), they are less likely to cause immunological responses such as those observed with murine anti-CD3 antibodies. The therapeutic agents of the present invention can be combined with each other. For example, a combination of antibodies against an ACT-4-L ligand with antibodies against an ACT-4 receptor is likely to provide a particularly effective blockade against T-cell activation. The agents of the invention can also be combined with traditional therapeutics, and can be used to lower the dose of such agents to levels below those associated with side effects. For example, other immunosuppressive agents such as antibodies to the α3 domain, T cell antigens (e.g., OKT4 and OKT3, CD28), B-cell antigen (B7 or B7-2), antithymocyte Globulin, as well as chemotherapeutic agents such as Cyclosporine, glucocorticoids, azathioprine, Prednisone can be used in

73

conjunction with the therapeutic agents of the present invention.

For destruction of a specific population of target cells, it can be advantageous to conjugate the therapeutic agents of the present invention to another molecule. For example, the agents can be joined to liposomes containing particular immunosuppressive agents, to a specific monoclonal antibody or to a cytotoxin or other modulator of cellular activity, whereby binding of the conjugate to a target cell population will result in alteration of that population. A number of protein toxins have been discussed *supra*. Chemotherapeutic agents include, for example, doxorubicin, daunorubicin, methotrexate, cytotoxin, and anti-sense RNA. Antibiotics can also be used. In addition, radion isotopes such as yttrium-90, phosphorus-32, lead-212, iodine-131, or palladium-109 can be used. The emitted radiation destroys the targeted cells.

2. Diseases and Conditions Amenable to Treatment

The pharmaceutical compositions discussed above are suitable for treating several diseases and conditions of the immune system.

A. Transplant Rejection

Over recent years there has been a considerable improvement in the efficiency of surgical techniques for transplanting tissues and organs such as skin, kidney, liver, heart, lung, pancreas and bone marrow. Perhaps

74

the principal outstanding problem is the lack of satisfactory agents for inducing immunotolerance in the recipient to the transplanted allograft or organ. When allogeneic cells or organs are transplanted into a host (i.e., the donor and donee are different individual from the same species), the host immune system is likely to mount an immune response to foreign antigens in the transplant (host-versus-graft disease) leading to destruction of the transplanted tissue. CD8⁺ cells, CD4⁺ cells and monocytes are all involved in the rejection of transplant tissues. The therapeutic agents of the present invention are useful to block alloantigen-induced immune responses in the donee (e.g., blockage or elimination of allogen-activation of CD4⁺ T-cells by antibodies to an ACT-4 receptor or ACT-4-L ligand) thereby preventing such cells from participating in the destruction of the transplanted tissue or organ.

b. Graft Versus Host Disease

A related use for the therapeutic agents of the present invention is in modulating the immune response involved in "graft versus host" disease (GVHD). GVHD is a potentially fatal disease that occurs when immunologically competent cells are transferred to an allogeneic recipient. In this situation, the donor's immunocompetent cells may attack tissues in the recipient. Tissues of the skin, gut epithelia and liver are frequent targets and may be destroyed during the

75

course of GVHD. The disease presents an especially severe problem when immune tissue is being transplanted, such as in bone marrow transplantation; but less severe GVHD has also been reported in other cases as well, including heart and liver transplants. The therapeutic agents of the present invention are used to block activation of, or eliminate, the donor leukocytes (particularly activated CD4⁺ T-cells and B-cells), thereby inhibiting their ability to lyse target cells in the host.

10

E. Autoimmune Diseases

A further situation in which immune suppression is desirable is in treatment of autoimmune diseases such as insulin-dependent diabetes mellitus, multiple sclerosis, stiff man syndrome, rheumatoid arthritis, myasthenia gravis and lupus erythematosus. In these diseases, the body develops a cellular and/or humoral immune response against one of its own antigens leading to destruction of that antigen, and potentially crippling and/or fatal consequences. Activated CD4⁺ T-cells are believed to play a major role in many autoimmune diseases such as diabetes mellitus. Activated B cells play a major role in other autoimmune diseases such as stiff man syndrome. Autoimmune diseases are treated by administering one of the therapeutic agents of the invention, which block activation of, and/or eliminate CD4⁺ T-cells and/or B-cells. Optionally, the autoantigen,

76

or a fragment thereof, against which the autoimmune disease is targeted can be administered shortly before, concurrently with, or shortly after the immunosuppressive agent. In this manner, tolerance can be induced to the autoantigen under cover of the suppressive treatment, thereby obviating the need for continued immunosuppression. See, e.g., Cobbold et al., WO 90/15152 (1990).

d. Inflammation

Inflammation represents the consequence of capillary dilation with accumulation of fluid and migration of phagocytic leukocytes, such as granulocytes and monocytes. Inflammation is important in defending a host against a variety of infections but can also have undesirable consequences in inflammatory disorders, such as anaphylactic shock, arthritis, gout and ischemia-reperfusion. Activated T-cells have an important modulatory role in inflammation, releasing interferon γ and colony stimulating factors that in turn activate phagocytic leukocytes. The activated phagocytic leukocytes are induced to express a number of specific cells surface molecules termed homing receptors, which serve to attach the phagocytes to target endothelial cells. Inflammatory responses can be reduced or eliminated by treatment with the therapeutic agents of the present invention. For example, antibodies against ACT-4 or ACT-4-L block activation of, or eliminate

activated, CD4⁺ cells, thereby preventing these cells from releasing molecules required for activation of phagocytic cell types.

e. Infectious Agents

The invention also provides methods of augmenting the efficacy of vaccines in preventing or treating diseases and conditions resulting from infectious agents. Therapeutic agents having the capacity to activate CD4⁺ T-cells and/or B-cells (e.g., certain monoclonal antibodies against an ACT-4 or ACT-4-L ligand) are administered shortly before, concurrently with, or shortly after the vaccine containing a selected antigen. The therapeutic agent serves to augment the immune response against the selected antigen. These methods may be particularly advantageous in patients suffering from immune deficiency diseases.

f. HTLV-I Infections

Antibodies against ACT-4-h-L-1 are also useful for killing HTLV-I-infected cells. As noted above, such cells express a gp34 antigen that is identical or nearly identical to ACT-4-h-1. These methods are usually performed in vivo or ex vivo on HTLV-I-infected individuals. However, the methods are also effective for killing HTLV-I-infected HRV cells in vitro. For example, the methods are particularly useful for protecting hospital workers from infection through contact with tissue samples under analysis. The risk of HTLV-I

infection can be reduced by treating the samples according to the present methods (provided of course that the samples are being tested for something other than the presence of HTLV-I).

Antibodies against ACT-4-h-1-5 L-1 and also antibodies against ACT-4-h-1 may be effective to reduce or eliminate perturbations of the immune system that have been observed in individuals suffering from HTLV-I infection. Such perturbations may result from the presence of ACT-4-h-L-1 as a surface antigen on HTLV-I infected T-cells, which would allow the infected T-cells to interact with CD4⁺ T-cells via an ACT-4 receptor.

g. Treatment of AIDS

HIV virus is known to infect human CD4⁺ T-cells by binding to the CD4 receptor. However, it is likely that for productive infection to occur the CD4 receptor must interact with another receptor present on the receptor of CD4⁺ T-cells. The identification of ACT-4 as a receptor on the surface of activated T-cells suggests that ACT-4 and/or its ligand ACT-4-L may interact with CD4 and contribute to HIV infection of T-cells. If so, therapeutically effective amounts of therapeutic agents targeted against ACT-4 or ACT-4-L may be effective in aborting HIV infection and thereby treating AIDS. These therapeutic agents may also be effective for killing HIV-infected CD4⁺ T-cells either in vivo or in vitro. In vitro methods have utility in e.g. protecting hospital workers from accidental infection as discussed above.

h. Treatment of Inflammatory Bowel Disease

It has been found that ACT-4-L-L-I and its specific binding analogues and partners including ACT-4 can be of use in connection with inflammatory bowel disease.

The tissue expression of ACT-4 was investigated

using the standard technique of indirect alkaline phosphatase immunohistochemical staining (see e.g.

Immunocytochemistry: Practical Applications in Pathology and Biology. J. Polak and S. van Noorden, eds. John

Wright and Sons, Bristol). Biopsy tissue samples of intestine from both ulcerative colitis and Crohn's disease patients stained positively with the anti-ACT-4 antibody L106. Clusters of L106+ cells were seen among the lymphoid cells infiltrating the lamina propria at

sites of inflammation. In samples of intestinal tissue from normals or in samples of uninvolvled intestinal tissue from patients only isolated, scattered L106+ cells were seen.

Accordingly the invention provides in-vivo and in-vitro diagnostic methods, and methods of treatment.

The following examples are offered to illustrate, but not to limit, the invention.

EXAMPLES**Example 1: A Monoclonal Antibody Against ACT-4-h-1**

Mice were immunized with PHA-transformed T-lymphoblasts. Splenocytes from immunized mice were fused with SP2/O myeloma cells and hybridomas secreting

antibodies specific for the T-cell clone were selected.

The hybridomas were cloned by limiting dilution. A monoclonal antibody, designated L106, produced by one of the resulting hybridoma, was selected for further characterization. The L106 antibody was found to have an IgG1 isotype. A hybridoma producing the antibody, designated HBL106 has been deposited as ATCC HB11483.

Example 2: Cellular Distribution of Polypeptide

Recognized by L106 Antibody

Samples containing the antibody L106 were made available to certain participants at the Fourth International Workshop and Conference on Human Leucocyte Differentiation Antigens (Vienna 1989) for the purpose of identifying tissue and cell types which bind to the L106 antibody. The data from the workshop are presented in Leukocyte Typing IV (ed. W. Knapp, Oxford U. Press, 1989) (incorporated by reference for all purposes) and an accompanying computer data base available from Walter R. Gilks, MRC Biostatistics Unit, Cambridge University, England. This reference reports the L106 antibody binds a polypeptide of about 50 kDa. This polypeptide was reported to be present on HUT-102 cells (a transformed T-cell line), PHA-activated peripheral blood lymphocytes, an EBV-transformed B-lymphoid cell line, and HTLV-II transformed T-cell line, PMA-activated tonsil cells, ConA- or PHA-activated PBUs, and PMA-activated monocytes. The polypeptide was reported to be substantially absent

81

on inter alia resting basophils, endothelial cells, fibroblasts, interferon γ -activated monocytes, peripheral non-T-cells, peripheral granulocytes, peripheral monocytes, peripheral mononuclear cells, peripheral T cells, and peripheral red blood cells.

The present inventors have obtained data indicating that the 50 kDa polypeptide (hereinafter "ACT-4-h-1 receptor") is preferentially expressed on the CD4⁺ sub species of activated T-cells. In one series of experiments, cell-specific ACT-4-h-1 expression was analyzed on unfractionated PBLs by a two-color staining method. PBL were activated with PHA for about two days (using the culture conditions described in Example 3), and analyzed for cell-surface expression of ACT-4-h-1 on different cellular subtypes by staining with two differently-labelled antibodies (FITC and PE labels). Labels were detected by FACS™ analysis essentially as described by Picker et al., *J. Immunol.* 150:1105-1121 (1993) (incorporated by reference for all purposes). One antibody, L106, was specific for ACT-4-h-1, the other antibody was specific for a particular leukocyte subtype. Fig. 1 shows three charts in which L106 staining is shown on the Y-axis of each chart, and anti-CD4, anti-CD8 and anti-CD19 staining as the X-axes of the respective charts. For the chart stained with anti-CD4, many cells appear as double positives (i.e., express both CD4 and ACT-4-h-1). For the chart stained with anti-CD8, far fewer cells appear as double positives. For the chart

82

stained with anti-CD19 (a B-cell marker), double-positive cells are substantially absent.

In another series of experiments expression of ACT-4-h-1 was analyzed by single-color staining on isolated cell types. Cells were stained with fluorescently labelled L106 antibody and the label was detected by FACS™ analysis. See Engleman et al., *J. Immunol.* 127:2124-2129 (1981) (incorporated by reference for all purposes). In some experiments, cells were activated by PHA stimulation for about two days (again using the culture conditions described in Example 3). The results from this experiment, together with those from the two-color staining experiment described *supra*, are summarized in Table 1. Table 1 shows that about 80% of activated CD4⁺ cells expressed ACT-4-h-1 with a mean channel fluorescence of >20, irrespective whether the CD4⁺ cells are isolated (one-color staining) or in unfractionated PBLs (two-color staining). The level of expression of ACT-4-h-1 on activated CD8⁺ cells is much lower than on activated CD4⁺ T-cells in the two-color staining experiment, and very much lower in the one-color staining. Thus, the extent of expression on activated CD8⁺ cells appears to depend on whether the CD8⁺ cells are fractionated from other PBLs before activation. In unfractionated CD8⁺ cells (two-color staining), about 10% of cells express ACT-4-h-1, with a mean channel fluorescence of about 4. In the fractionated cells, only about 4% of cells express ACT-4-h-1 with a mean channel

fluorescence of about 2. These data suggest that ACT-4-h-1 is expressed only on a small subtype of activated CD8⁺ cells and that this subtype is somewhat more prevalent when the CD8⁺ cells are activated in the presence of other PBLS.

Table 1 also indicates that ACT-4-h-1 was substantially absent on all resting leukocyte subtypes tested (i.e., CD4⁺ T-cells, CD8⁺ T-cells, CD19⁺ B-cells, CD14⁺ monocytes, granulocytes and platelets), and was also substantially absent on activated B-cells and monocytes. ACT-4-h-1 was also found to be substantially absent on most tumor cell lines tested. However, Molt3, Raji and NC37 cell lines did show a low level of expression.

84

TABLE I
CELL SPECIFICITY OF ACT-4-h-1 EXPRESSION
Expression of ACT-4-h-1

			<u>Cells</u>	<u>MCF¹</u>
when the CD8 ⁺ cells are activated in the presence of other PBLs.	Table 1 also indicates that ACT-4-h-1 was substantially absent on all resting leukocyte subtypes tested (i.e., CD4 ⁺ T-cells, CD8 ⁺ T-cells, CD19 ⁺ B-cells, CD14 ⁺ monocytes, granulocytes and platelets), and was also substantially absent on activated B-cells and monocytes. ACT-4-h-1 was also found to be substantially absent on most tumor cell lines tested. However, Molt3, Raji and NC37 cell lines did show a low level of expression.			
0				
5				
10	Two Color Staining		<2	<2
15	CD4 ⁺ T-Cells (resting) CD4 ⁺ T-Cells (activated) CD8 ⁺ T-Cells (resting) CD8 ⁺ T-Cells (activated) CD19 ⁺ B-Cells (resting) CD19 ⁺ B-Cells (activated) CD14 ⁺ Monocytes (resting) CD14 ⁺ Monocytes (activated)	80 10 10 10 10 10 10 10	25 <2 <2 <2 <2 <2 <2 <2	25 <2 <2 <2 <2 <2 <2 <2 <2
20	One Color Staining		<2	3
25	PBUs (resting) PBUs (activated) CD4 ⁺ (resting) CD4 ⁺ (activated) CD8 ⁺ (resting) CD8 ⁺ (activated)	50 50 80 80 4	27 <2 <2 <2 <2	<2 <2 <2 <2 <2
30	Granulocytes Platelets	<2 <2	<2 <2	<2 <2
35	Tumor Lines			
40	Molt-4, CEM, Hut 78, H9, Jurkat HPB-ALL, Sezary, T-AU Molt-3	20 20 3	<2 <2 <2	<2 <2 <2
45	B-LCL, Arent, RML, JY, KHY, PGf MSAB, CESS, 9037, 9062 Dandi, Ramos, Namalwa Raji, NC37 U937, THP-1, HL-60 Kela, KG62, HEL	30 30 30 30 30	<2 <2 <2 <2 <2	<2 <2 <2 <2 <2

50 MCF = Mean Channel Fluorescence.

²Cells indicated as "activated" had been stimulated with PHA for about three days.

Example 3: Time Course of ACT-4-h-1 Expression Responsive to CD4⁺ T-cell Activation

CD4⁺ T-cells were tested for expression of ACT-4-h-1 receptors in response to various activating stimuli. CD4⁺ T-cells were purified from peripheral blood mononuclear cells by solid-phase immunoadsorption ('panning'). 5 x 10⁴ CD4⁺ T-cells were cultured with an activating agent in microtiter wells containing RPMI medium supplemented with 10% human serum. Three different activating agents were used: (1) 5 x 10⁴ irradiated (3000 rads) monocytes, (2) PHA (1 µg/ml) and (3) tetanus toxoid (5 µg/ml). ³H-thymidine was added to the cultures 12-16 h before harvest. After harvest, cells were tested for the expression of cell surface antigens by incubation with various labelled antibodies (Li06, anti-CD4 I5 and anti-CD8), as described by Engleman et al., J. Immunol. 127:2124-2129 (1981).

Figure 2 shows the appearance of ACT-4-h-1 in response to alloantigen activation. Before activation, no expression was observed. The percentage of cells expressing the ACT-4-h-1 receptor increases with time, peaking at about 30% after about seven days of alloantigen activation. The results also show that essentially all cells expressing ACT-4-h-1 also expressed the CD4 receptor and that essentially no such cells expressed the CD8 receptor. Figure 3 presents similar data for the appearance of ACT-4-h-1 in response to tetanus toxoid activation. Again, the percentage of cells expressing ACT-4-h-1 peaked at about seven days. However, at this time a higher percentage of cells (about 60%) expressed the receptor. Figure 4 presents similar data for the appearance of ACT-4-h-1 on CD4⁺ T-cells in response to PHA activation. In this situation, the percentage of CD4⁺ T-cells expressing the receptor peaks at about 65% after three days of activation.

It is concluded that ACT-4-h-1 is a CD4⁺ T-cell activation antigen that is expressed in response to diverse activating stimuli.

Example 4: Cloning ACT-4-h-1 cDNA

The cDNA clone for the ACT-4-h-1 receptor was isolated using a slightly modified COS cell expression system, first using by Aruffo & Seed, supra. RNA was isolated from 72-hour PHA activated human peripheral blood lymphocytes. Total RNA was extracted with TRI-reagent (Molecular Research Center), and poly(A)+ RNA was isolated by oligo dT-magnetic bead purification (Promega). cDNA was synthesized by the method of Gubler & Hoffman, Gene 25:263-269 (1982) using superscript reverse transcriptase (Gibco/BRU) and an oligo dT primer. The blunted cDNA was ligated to non-self-complementary BstXI adaptors and passed over a sephadryl S-400 spin column to remove unligated adaptors and small fragments (<300 base pairs). The linked cDNA was then ligated into a BstXI cut eukaryotic expression vector, pCDNA-IRI, an ampicillin resistant version of pCDNA-I(Invitrogen). The precipitated and washed products of the ligation reaction were electroporated into E. coli strain WM1100(BioRad). Plating and counting of an aliquot of the transformed bacteria revealed a total count of 2 million independent clones in the unamplified library. Average insert size was determined to be 1.2 kb. The bulk of the library was amplified in liquid culture, 250 ml standard LB media. Plasmid was recovered by alkaline lysis and purified over an ion-exchange column (Qiagene).

Sub-confluent COS-7 cells were transfected with the purified Plasmid DNA by electroporation. Cells were plated on 100mm dishes and allowed to grow for 48 hours. Cells were recovered from the plates with PBS-EDTA solution, incubated 30 with monoclonal antibody Li06, and were panned according to standard procedures. A second round panning revealed enrichment as numerous COS cells adsorbed to the plates. Episomal DNA was recovered from the immunoselected cells by the Hirt method, and electroporated into bacteria for amplification.

Bacteria transformed with Plasmid from the second round Hirt preparation were diluted into small pools of about

87

100 colonies. The pools were amplified and their DNA purified and tested for the ability to confer expression of the L106 antigen on COS-7 cells by immunofluorescence. Phycoerythrin-conjugated L106 antibody was used to stain COS-7 cell monolayers and the cells were then examined by manual immunofluorescence microscopy. Miniprep DNA from four out of eight pools was positive when tested for expression. The pool with the best expression, pool E, was divided into smaller pools of ~ 12 colonies. Three out of eight sub-pools were positive, and sub-pool E1 was plated to allow for the analysis of single colonies. Clone E1-27 was found to confer high level expression of ACT-4-h-1 receptor on the surface of transfected COS cells.

15 Example 5: cDNA Sequence Analysis

The insert from the clone designated E1-27 was subcloned into pBluescript and sequenced by the dideoxy chain termination method, using the T7 polymerase autoradi sequencing kit (Pharmacia) on an ALF sequencer (Pharmacia). Restriction mapping revealed several convenient sites for subcloning. Five subclones were generated in pBluescript and were sequenced on both strands with M13 forward and universal primers.

The cDNA and deduced amino acid sequences of ACT-4-h-1 are shown in Fig. 5. The ACT-4-h-1 cDNA sequence of 1,137 base pairs contains a 14-bp 5' untranslated region and a 203-bp 3' untranslated region. An ATAAA polyadenylation signal is present at position 1,041 followed by an 80-bp poly A tail starting at position 1,057. The longest open reading frame begins with the first ATG at position 15 and ends with a TGA at position 846. The predicted amino acid sequence is that of a typical type 1 integral membrane protein. Hydrophobicity analysis revealed a putative signal sequence following the initiating ATG, with a short stretch of basic residues followed by a longer stretch of hydrophobic residues. A predicted signal peptide cleavage site is present at residue 22 or 24 (the latter being the more likely by the criteria of

88

WO 9521915

von Heijne, Nucleic Acids Res. 14:4683-4690 (1986)) (incorporated by reference for all purposes), leaving a mature protein of 253 amino acid residues (or 255 amino acids, if cleavage occurs at the less probable site). Hydrophobicity analysis also reveals a single large stretch of 27 hydrophobic residues predicted to be the transmembrane domain, which predicts an extracellular domain of 189 (or 191) amino acids and an intracellular domain of 37 amino acids. The extracellular domain is cysteine rich, where 18 cysteines are found within a stretch of 135 amino acids. The predicted molecular mass (M_r) for the mature protein is 27,400, and there are two potential N-glycosylation sites at amino acid residues 146 and 160.

Comparison of the amino acid sequence of ACT-4-h-1 15 with known sequences in the swiss-prot database using the BLAZE program reveals a sequence similarity with members of the nerve growth factor receptor superfamily. Amino acid sequences are at least 20% identical for NGF-R, TNF-R, CD40, 41-BB, and fas/APO-1, and 62% for OK-40, allowing for gaps 20 and deletions. Alignments of the various proteins reveal the conservation of multiple cysteine rich motifs. Three of these motifs are present in ACT-4-h-1 and OK-40, compared with four such motifs in NGF-R and CD40.

Comparison of the nucleotide sequence of ACT-4-h-1 25 with known sequences in the Genbank and EMBL databases using the programs BLAST and PASTOR revealed a high degree of sequence similarity with only one member of the nerve growth factor receptor family, OK-40. Allowing for gaps and insertions, the sequence identity is 66%. Comparison of the 30 ACT-4-h-1 and OK-40 nucleotide sequences reveals that both contain a 14-bp 5' untranslated region, and both contain approximately 80-bp poly A tails. In ACT-4-h-1, however, there is a slight lengthening of the 3' untranslated region from 187-bp to 209-bp, and there is a lengthening of the 35 coding region from 816-bp to 834-bp, a difference of 18-bp or 6 amino acid insertions. Aligning the two amino acid insertions sequences reveals that four of the amino acid insertions occur

89

prior to the signal sequence cleavage site. Thus, the mature ACT-4-h-1 receptor protein contains one more amino acid residue than OX-40 (i.e., 253 vs. 252 amino acids). Remarkably, the ACT-4-h-1 nucleotide sequence is much more GC rich, than the OX-40 sequence (70% v. 55%) indicating that the two sequences will not hybridize under stringent conditions.

Example 6: Production of Stable ACT-4-h-1 Transfectants

An XbaI-HindIII fragment was excised from the construct described in Example 4, and inserted into XbaI/HindIII-digested pcDNA-I-neo (Invitrogen) to generate an expression vector termed ACT-4-h-1-neo (Fig. 6). This vector was linearized with SfiI and electroporated into three eukaryotic cell lines. These cell lines were SP2/0 (a mouse myeloma derived from the Balb/c strain), Jurkat (a transformed human T-cell line) and COS-7 (an adherent monkey cell line). After a 48-h recovery period, transformed cells were selected in 1 mg/ml G418 (Gibco). After three weeks of selection, neomycin resistant cell lines were incubated with a saturating concentration of L106 antibody, washed and overlayed onto 100 mm petri dishes coated with goat anti-mouse IgG to select for cells expressing ACT-4-h-1. After washing off unbound cells, adherent cells were recovered and expanded in tissue culture. Cell lines were subject to two further rounds of panning and expression. The resulting cell lines were shown by direct immunofluorescence staining to express abundant ACT-4-h-1 (Fig. 7).

The same strategy and principles are used to obtain a stable cell line expressing ACT-4-L-h-1 (See Example 10). **Example 7: Production of an ACT-4-h-1-Immunoglobulin Fusion Protein** A soluble fusion protein has been constructed in which the extracellular domain of ACT-4-h-1 is linked via its C-terminal to the N-terminal of the constant domain of a human immunoglobulin. The vector encoding ACT-4-h-1 described in Example 4 was cleaved with SmaI and NotI to excise all ACT-4-

90

h-1 sequences downstream of the SmaI site including the transmembrane, cytoplasmic and 3' untranslated regions. The remaining region encodes the soluble extracellular portion of ACT-4-h-1 (Fig. 8). The source of the immunoglobulin constant region to be joined to the ACT-4-h-1 extracellular domain was a plasmid termed 5K 41BB-Eg1 (Proc. Natl. Acad. Sci. (USA) 89: 10360-10364) (incorporated by reference for all purposes). This plasmid contains a 1.3 kb BamHI/Eg1 genomic fragment encoding the hinge, CH2 and terminal CH3 domains of human Ig gamma 1. The fragment required modification for insertion into the SmaI/NotI ends of the ACT-4-h-1 vector, while preserving the peptide reading frame across the SmaI junction to be formed by blunt-end ligation. The vector 5K-41BB-Eg1 was cut with BamHI and the resulting 5' extensions were filled with Klenow fragment. The vector was then cut with Eg1 releasing the 1.3 kb fragment with blunt and NotI compatible ends. This fragment was ligated with SmaI/NotI digested ACT-4-h-1 vector. The ligation mix was electroporated into E. coli and multiple transformant clones screened with PCR using ACT-4-h-1 and IgG1 nucleotide fragments as primers.

Plasmids containing the ACT-4-h-1-IgG1 coding were electroporated into COS cells. The cells were allowed to grow for five days at which point their supernatants were harvested and sterile filtered through a .2 micron membrane. The supernatants were tested for expression of ACT-4-h-1-IgG1 by dot blotting. Supernatants were blotted onto nitrocellulose and blocked with 5% nonfat dry milk. Replica blots were probed with antibody L106 or alkaline phosphatase-labelled goat anti-human immunoglobulin IgG (American Qualex). Antibody L106 was detected with an alkaline phosphatase labelled goat anti-mouse IgG. NBT/BCIP (Pierce) was used as a colorimetric substrate. High producing positive clones were sequenced at the junction site to confirm proper vector construction. The resulting fusion gene is depicted in Fig. 9.

Example 8: Identification of Cells Types Expressing a Ligand to ACT-4-h-1

Cell types expressing a ligand to ACT-4-h-1 were identified by indirect staining combined with flow cytometry

using the ACT-4-h-1 recombinant immunoglobulin fusion protein described in Example 7 (hereinafter ACT-4-h-1-Rg) as a probe.

Bound fusion protein was detected using phycoerythrin-conjugated anti-human Ig. These experiments revealed that a ligand to ACT-4-h-1 was expressed at low levels on a few B-cell lines, including a Burkitt lymphoma cell line (Jijoye), and the EBV-transformed LCL's 9037, 9059, and MSAB. These cell lines scored 5% positive with a MCF of 3. See Table 2. With the cell line Jijoye, it was possible to enrich for cells staining positive by the panning procedure to yield a cell line Jo-5, which stained 90% positive with a MCF of 10.

Other cell lines tested, including PBMC's and purified subpopulations of freshly isolated T-cells, B-cells, monocytes, dendritic cells, most T-cell tumor lines and myelomonocytic tumor cell lines, were substantially absent of a ligand to ACT-4-h-1. However, two HTLV-I infected T cell lines, HUT-102 and MT-2 expressed ACT-4-h-1, the latter at extremely high levels.

The experiment was repeated after activation of cells using either PHA or a combination of PMA/ionomycin. PBMC's activated with 2 μ g/ml of PHA for three days stained between 2-10% positive for a ligand to ACT-4-h-1, depending on the donor. Activation of B-ICL cells and Burkitt lymphoma lines using a combination of PMA (10 ng/ml) and ionomycin (500 ng/ml) induced substantial expression of ligand for some cell lines, particularly those such as MSAB that showed low levels of expression in the resting state. See Table 2. Unfractionated B cells also showed preferential expression of ligand (15% cells positive, MFC=5). Time course studies on MSAB cells indicated that ligand expression begins on day 2 following activation, and peaks on day 3 or 5. PMA/ionomycin-activation also induced preferential expression of ligand in erythroleukemia cell lines and in one of the three

myelomonocytic cell lines tested, THP-1. PMA/ionomycin activation also induced a low level of expression of ligand in the T-cell lines but not in the other T-cell lines tested.

Table 2:

5 Expression of Ligand to ACT-4-h-1 on Different Cell Types

TUMOR CELL LINE SCREEN

B-ICL	Resting		Activated	
	10	15	20	25
MSAB	2-5%	mcf ^a 4	80%	mcf 21
CES5	<2		70%	mcf 25
JY	<2		40%	9
REMI	<2		40%	11
9059	2-5%	mcf 4	40%	6
SKE	<2		30%	3
9037	2-5%	mcf 4	25%	5
9062	<2		10%	5
PGF	<2		6%	10
ARENT	<2		4%	5
KHY	<2		3%	5

BURKITT LYMPHOMA	
Jijoye	20%
Daudi	<2
Naralwa	<2
Raji	<2

OTHER B CELL	
30 (Pre B) (B-A11)	NC-37
SB	<2

T-CELL	
HSB-2	<2
Jurkat	<2

93

94

Mol +4	<2	<2
Mol +3	<2	<2
T-CELL (cont'd)		
	Resting	Activated
HPB-ALL	<2	<2
HU +78	<2	<2
10 H9	<2	<2
VB	<2	<2
MYELO MONOCYTIC		
THP-1	25*	mcf 5
V937	<2	<2
HL60	<2	<2
ERYTHRO LEUKEMIA		
HEL	<2	25*
K562	2*	25*
HTLV-I INFECTED T-CELLS		
HUT-102	30*	mcf 4
MT-2	100*	100

25
 1 PMA/Ionomycin
 2 * Positive cells
 3 Mean channel fluorescence
 30

The CDNA clone for the ligand was isolated using a slightly modified COS cell expression system, first developed 35 by Aruffo & Seed, supra. RNA was isolated from 72-hour PMA/ionomycin-activated human EBV-transformed B cells (cell

line MSAB). Total RNA was extracted with TRI-reagent (Molecular Research Center), and poly(A)+ RNA was isolated by oligo dT-magnetic bead purification (Promega). cDNA was synthesized by the method of Gubler & Hoffman, Gene 25:263-269 (1982) using superscript reverse transcriptase (Gibco/BRL) and an oligo dT primer. The blunted cDNA was ligated to non-self-complementary BstXI adaptors and passed over a Sephadryl S-500 column to remove unligated adaptors and small fragments (<300 base pairs). The linker cDNA was then ligated into a BstXI cut eukaryotic expression vector, pcDNA (Invitrogen). The ligation products were precipitated, washed and electroporated into E. coli strain MC1061/P3 generating an unamplified library of 100 million independent clones. The average insert size in the library was 1 kb. The bulk of the library was amplified in 250 ml standard LB media. Plasmid DNA was recovered by alkaline lysis and purified over an ion-exchange column (Qiagen).

Sub-confluent COS-7 cells were transfected with the purified plasmid DNA by electroporation. Cells were plated on 100mm dishes and allowed to grow for 48 hours. Cells were recovered from the plates with PBS-EDTA solution, incubated with monoclonal antibody ACT-4-h-1-Rg, and panned according to standard procedures. A second round panning numerous COS cells adsorbed to the plates showing enrichment for cells expressing ligand. Episomal DNA was recovered from the immunoselected cells by the Hirt method, and electroporated into bacteria for amplification.

Bacteria transformed with plasmid from the second round selection were cloned and amplified. DNA from 30 individual clones was purified and tested for the ability to confer expression of a ligand to ACT-4-h-1 in COS-7 cells. Phycoerythrin-conjugated ACT-4-h-1-Rg was used to stain COS-7 cell monolayers and the cells were then examined by manual immunofluorescence microscopy. Clones #2, 26, and 30 gave 35 high level expression of ACT-4-h-1-Rg binding activity.

Example 2: Cloning cDNA Encoding an ACT-4-h-1 Ligand

The cDNA clone for the ligand was isolated using a slightly modified COS cell expression system, first developed 35 by Aruffo & Seed, supra. RNA was isolated from 72-hour PMA/ionomycin-activated human EBV-transformed B cells (cell

95

Example 10: Sequence Analysis of a Ligand to ACT-4-L-h-1

The insert from clone 26 in Example 9 was subcloned into pBluescript at the HindIII and XbaI cloning sites. The clone was sequenced by the dideoxy chain termination method, using a T7 polymerase-based autoradi sequencing kit (Pharmacia) on an ALF sequencer (Pharmacia). Three subclones were generated in pBluescript and were sequenced on both strands with M13 forward and universal primers. The cDNA and predicted amino acid sequences of clone 26 are shown in Fig. 10. The polypeptide formed by the predicted amino acid sequence is designated ACT-4-L-h-1.

The ACT-4-L-h-1 cDNA sequence contains 1079 base pairs, with a 137 bp 5' UTR and a 379 bp 3' UTR. An AATAAA polyadenylation signal is present at position 1024 followed by a 20 base poly A tail beginning at position 1049. Sequence analysis reveals a single open reading frame which encodes a 183 amino acid polypeptide, with a calculated molecular weight of 21,000. The open reading frame begins with the first ATG at position 149 and ends with a TGA at position 698. The ATG is flanked with a Kozak consensus initiation sequence with an A position at -3 and a G at +4. Hydrophobicity analysis reveals that the predicted amino acid sequence is that of a type II membrane protein with a single transmembrane domain of approximately 27 aa in the amino terminal portion of the protein. Also there are four N-linked glycosylation sites in the C-terminal portion of the molecule.

Comparison of the nucleotide sequence of ACT-4-L-h-1 with known sequences in the Genbank and EMBL databases reveals no significant homology to known genes except for a gene encoding a protein designated gp34 by Miura et al., Mol. Cell Biol. 11:1313-1325 (1991). The cDNA sequence of the coding region of the ACT-4-L-h-1 ligand is identical to that of gp34. However, the ACT-4-L-h-1 cDNA contained an additional 112 nucleotides at the 5' end compared with the gp34 sequence. Because the additional nucleotides occur within the 5' untranslated region, their presence is unlikely to alter the expression product. Most likely, the ACT-4-L-h-1 clone was

96

derived from a more complete reverse transcript and is more representative of the *in vivo* 5' end. Possibly the extra sequence could be involved in regulating the translation of the protein.

Comparison of the predicted amino acid sequence of the ACT-4-L-h-1 ligand with known sequences in the Protein Information Resource (PIR) database using the FastDB program revealed an identity with gp34, and a very weak homology with TNF alpha. A secondary structure prediction algorithm developed by Chou & Fasman predicts that the ACT-4-L-h-1 ligand and TNF-alpha are both likely to form significant amounts of beta structures. This prediction is consistent with the observation that other members of the TNF family of proteins are all conformed or predicted to form beta jelly roll configurations rich in beta structures.

For the purposes of clarity and understanding, the invention has been described in these examples and the above disclosure in some detail. It will be apparent, however, that certain changes and modifications may be practiced within the scope of the appended claims. All publications and patent applications are hereby incorporated by reference in their entirety for all purposes to the same extent as if each were so individually denoted.

Comparison of the nucleotide sequence of ACT-4-L-h-1 with known sequences in the Genbank and EMBL databases reveals no significant homology to known genes except for a gene encoding a protein designated gp34 by Miura et al., Mol. Cell Biol. 11:1313-1325 (1991). The cDNA sequence of the coding region of the ACT-4-L-h-1 ligand is identical to that of gp34. However, the ACT-4-L-h-1 cDNA contained an additional 112 nucleotides at the 5' end compared with the gp34 sequence.

Because the additional nucleotides occur within the 5' untranslated region, their presence is unlikely to alter the expression product. Most likely, the ACT-4-L-h-1 clone was

WHAT IS CLAIMED IS:

97

6. A specific binding partner according to claim 5 that exhibits at least eighty percent sequence identity to the amino acid sequence of Figure 10.

98

1. A specific binding partner for an ACT-4 receptor polypeptide which

(a) is other than the monoclonal antibody designated L1.06 produced by the hybridoma HB1106 deposited as ATCC HB11483; and

(b) has an amino acid sequence other than the complete amino acid sequence shown in Figure 10.

2. A specific binding partner according to claim 1 which is other than a ligand in the form of an antibody.

3. A specific binding partner according to claim 1 or claim 2 which is a fragment, variant, mutant or derivative of the amino acid sequence shown in Figure 10 or a homologue or analogue thereof, optionally in the form of a conjugate or complex.

4. A specific binding partner according to claim 4 in the form of a conjugate or complex which further comprises a toxin or a label.

5. A specific binding partner according to claim 3 having a segment of at least 5 contiguous amino acids from the amino acid sequence shown in Figure 10.

10.

11. A specific binding partner according to claim 10 wherein the extracellular domain is full-length.

15

10.

15

10.

20

15

10.

25

10.

25

10.

30

10.

35

10.

40

10.

45

10.

50

99

12. A specific binding partner according to any one of the preceding claims which is glycosylated.

13. A specific binding partner according to any one of the preceding claims which further comprises a linked polypeptide.

14. A specific binding partner according to claim 13, wherein the linked polypeptide sequence is covalently conjugated.

15. A specific binding partner according to claim 13, comprising a fusion protein in which a polypeptide chain contains amino acid sequence corresponding to the specific binding partner and further amino acid sequence corresponding to the linked polypeptide.

16. A specific binding partner according to claim 13 wherein the said linked polypeptide is an immunoglobulin constant region.

17. A specific binding partner according to any one of the preceding claims which is in soluble form.

18. A specific binding partner according to any one of the preceding claims which is labelled.

19. A specific binding partner according to any one of

100

the preceding claims which inhibits in vitro activation of CD4⁺ T cells expressing an ACT-4 receptor on their surface.

5 20. A specific binding partner according to any one of the claims 1-19 which stimulates in vitro activation of CD4⁺ T cells expressing an ACT-4 receptor on their surface.

10 21. A specific binding partner according to any one of the preceding claims which comprises a fragment which competes with the specific binding partner shown in Figure 10 for binding to an antibody.

15 22. A binding moiety with specificity for a specific binding partner according to any one of claims 1-21; which binding moiety is other than the ACT-4 receptor polypeptide and which is not cross reactive with a polypeptide which has the complete amino acid sequence shown in Figure 10.

20 23. A binding moiety according to claim 22 which comprises an antibody binding domain.

25 24. A binding moiety with specificity for an ACT-4 receptor polypeptide which comprises:

(a) part or all of a human antibody binding domain;

101

or

(b) a humanised portion of an antibody.

25. A binding moiety according to claim 22 which comprises a humanised portion of an antibody and a non-human antibody binding domain.

26. A binding moiety according to claim 24 or claim 254 which comprises a Fab or F(ab)', of an antibody.

27. A binding moiety according to any one of claims 23 to 26 which comprises a monoclonal antibody.

28. A binding moiety according to claim 27 which comprises a humanized monoclonal antibody comprising a humanized heavy chain and a humanized light chain:

(1) the humanized light chain comprising three complementarity determining regions (CDR1, CDR2 and CDR3) having amino acid sequences from the corresponding framework sequence; and

20 (2) the humanized heavy chain comprising three complementarity determining regions (CDR1, CDR2 and CDR3)

25 identical to a human light chain variable region framework sequence; and

(2) the humanized heavy chain comprising three complementarity determining regions (CDR1, CDR2 and CDR3)

102

having amino acid sequences from the corresponding complementarity determining regions a heavy chain of the nonhuman antibody, and having a variable region framework sequence substantially identical to a human heavy chain variable region framework sequence;

5 wherein the humanized antibody specifically binds to the extracellular domain of the ACT-4-L-h-1 ligand with a binding affinity having a lower limit of 10¹¹ M⁻¹ and an upper limit that is within five-fold of the binding affinity of the nonhuman antibody.

10 29. A binding moiety according to any one of claims 22-28 wherein the specific binding partner for the ACT-4 receptor polypeptide or the ACT-4-L-h-1 ligand is on the surface of a B cell and the binding of the binding moiety to the specific binding partner or ligand inhibits activation of the B cell.

15 30. A binding moiety according to claims 22-28 wherein the specific binding partner for the ACT-4 receptor polypeptide or ACT-4-L-h-1 ligand is on the surface of a B cell and the binding of the binding moiety to the specific binding partner or ligand stimulates activation of the B-cell.

20 31. A binding moiety according to any one of claims 22-28 wherein the specific binding partner for the ACT-4 receptor polypeptide or the ACT-4-L-h-1 ligand is on the

receptor polypeptide or the ACT-4-L-h-1 ligand is on the

25

25

26

27

28

29

30

31

surface of a B cell and the binding of the antibody to the ligand inhibits the capacity of the B-cells to activate CD4⁺ T-cells.

5. 32. A binding moiety comprising a human monoclonal antibody that specifically binds to an extracellular domain of a specific binding partner for an ACT-4 receptor polypeptide.

10. 33. A nucleic acid segment which codes for a specific binding partner for part or all of an ACT-4 receptor polypeptide which has a nucleic acid sequence other than a nucleic acid sequence coding for the complete amino acid sequence shown in Figure 10.

15. 34. A nucleic acid segment which codes for a specific binding partner according to any one of claims 1-19.

20. 35. A nucleic acid segment according to claim 33 which comprises at least 25 contiguous nucleotides between nucleotides 1 and 112 of the 5'-untranslated region of the sequence shown in Fig. 10.

25. 36. A nucleic acid segment according to claim 33 having between 15 and 500 contiguous nucleotides from the sequence shown in Fig. 10.

37. A nucleic acid sequence which codes for a binding

103 moiety according to any one of claims 22-32.

104

38. A replicable expression vector which includes a nucleic acid segment according to any one of claims 33-37.

5. 39. A prokaryotic or eukaryotic host organism which has been transformed to include an expression vector according to claim 38.

10. 40. An isolated population of cells substantially enriched in B-cells expressing a specific binding partner for an ACT-4 receptor polypeptide on their surface.

15. 41. An isolated stable cell line expressing a specific binding partner for an ACT-4 receptor polypeptide on its surface.

20. 42. A pharmaceutical composition comprising a specific binding partner for an ACT-4 receptor which is other than the monoclonal antibody designated L106 produced by the hybridoma HBL106 deposited as ATCC HB11483; in combination with a pharmaceutically acceptable carrier.

25. 43. A pharmaceutical composition comprising a specific binding partner according to any one of claims 1-19; in combination with a pharmaceutically acceptable carrier.

105

44. A pharmaceutical composition comprising a specific binding partner for a ACT-4 receptor which has the amino acid sequence shown in Figure 10 or fragment, variant, mutant or derivative thereof; in combination with a pharmaceutically acceptable carrier.

45. A pharmaceutical composition comprising a binding moiety other than the ACT-4 receptor polypeptide, with specificity for a specific binding partner for an ACT-4 receptor polypeptide, in combination with a pharmaceutically acceptable carrier.

46. A pharmaceutical composition according to claim 45 wherein the binding moiety is as defined in any one of claims 22-32.

47. A method of modifying an immune response in a patient, the method comprising administering an effective amount of a pharmaceutical composition according to any one of claim 42-46.

48. The method of claim 47, wherein the administration step is performed *ex vivo*.

49. The method of claim 47 or 48 wherein the immune response of the patient is suppressed.

50. A method according to any one of claims 47 to 49 for

106

use in the treatment of transplant rejection, GVHD, autoimmune disease, inflammation, infectious agents, HTLV, infected cells or HIV.

51. A method according to any one of claims 47 to 49 for use in the treatment of inflammatory bowel disease or disorder.

52. A specific binding partner according to any one of claims 1-21 or a binding moiety according to any one of claims 22-32 for use in the modification of an immune response.

53. A method of screening for immunomodulating agents able to recognise ACT-4, the method comprising: contacting a specific binding partner for an ACT-4 receptor polypeptide with a material to be tested; and detecting binding between the specific binding partner and the agent, the material under test.

20

54. A method of screening for immunomodulatory agents able to affect the recognition of ACT-4 receptor polypeptide by its specific binding partner, the method comprising: contacting together (a) a specific binding partner for an ACT-4 receptor polypeptide, (b) an ACT-4 receptor or specific binding analogue thereof, and (c) an agent under test; and detecting binding between components (a) and (b).

25

55. The method of claim 53 or claim 54, wherein the specific binding partner for an ACT-4 receptor polypeptide is immobilized to a solid surface.

56. A method of inducing an immune response to a selected antigen comprising:
administering a binding moiety according to claim 30 to a patient; and
exposing the patient to the selected antigen.

57. A method of monitoring activated CD4⁺ T-cells, the method comprising:
contracting cells with a specific binding partner for an ACT-4 receptor polypeptide that specifically binds to an extracellular domain of said receptor; and
detecting specific binding between the said specific binding partner and the cells to indicate the presence of the activated CD4⁺ T-cells.

58. A method according to claim 57 wherein the cells comprise a tissue sample from a patient and the method is carried out *in vitro*.

59. A method of inhibiting infection of CD4⁺ T-cells by a human immune deficiency virus, the method comprising contacting the CD4⁺ T-cells with an antibody that specifically binds to an extracellular domain of the ACT-4 receptor.

107

108

60. An extracellular domain comprising at least five contiguous amino acids from the extracellular domain of the protein shown in Figure 10, or mutants, variants or derivatives thereof, that can bind to ACT-4.

5

61. A kit for detecting activated CD4⁺ T-cells which comprises a specific binding partner for ACT-4 receptor according to any one of claims 1 to 21.

10

62. A specific binding partner according to any one of claims 1 to 21 or a binding moiety according to any one of claims 22 to 32 for use in the preparation of a medicament for use in modifying a patients immune response.

15

63. A method of producing a specific binding partner for an ACT-4 receptor according to any one of claims 1 to 21 or a binding moiety of any one of claims 22 to 32 which comprises culturing a host organism according to claim 39.

20

64. Use of polypeptide having amino acid sequence as shown in Figure 10 or specific binding partners according to claim 1 in specific binding reactions for recognition of ACT-4 receptors or of specific binding analogues thereof.

25

65. Use of ACT-4 receptors or specific binding analogues

thereof in specific binding reactions for recognition of polypeptides having the amino acid sequence shown in Figure 10 or of specific binding partners according to claim 1..

5

66. A soluble polypeptide which is a specific binding agent capable of specific binding with ACT-4.

67. A polypeptide according to claim 66 having the amino acid sequence of Figure 10 except for the transmembrane subsequence thereof.

68. A composition comprising a specific binding partner according to claim 1 or a specific binding partner polypeptide having the complete amino acid sequence shown in Figure 10, carried on the surface of a preparation of liposomes, e.g. by a transmembrane sequence.

69. A method of detecting an analyte which comprises a specific binding partner for ACT-4 receptor polypeptide e.g. in a tissue sample such as a biopsy sample or a blood sample: which method comprises contacting the analyte with a first reagent comprising a

15

polypeptide e.g. in a tissue sample such as a biopsy sample or a blood sample, which method comprises contacting the analyte with a first reagent comprising a specific binding partner for an ACT-4 receptor polypeptide e.g. in a tissue sample such as a biopsy sample or a blood sample, which method comprises

70. A method of detecting an analyte which comprises a substance having complementary binding specificity to a specific binding partner for an ACT-4 receptor

5 specific binding partner fro an ACT-4 receptor polypeptide, a second reagent comprising a specific binding agent or similar or of complementary binding specificity as the analyte, there being provided a label for the second reagent, and detecting or quantitating the specific binding of the second reagent to its partner.

15

71. A diagnostic method according to claim 69 or 70 for detection of an inflammatory condition, carried out on a biopsy sample from a patient possibly having an inflammatory condition, e.g. an inflammatory bowel disease or disorder.

20

72. A kit for carrying out a specific binding assay for detection or quantitation of an analyte that comprises a specific binding partner for an ACT-4 receptor polypeptide, or an ACT-4 receptor or a specific binding analogue thereof: wherein said kit comprises a first reagent comprising a specific binding agent that can recognize the analyte, a second reagent comprising a

25

26 second reagent comprising a specific binding agent of similar or of complementary binding specificity as the analyte, there being provided a label for the second reagent, and detecting or quantitating the specific reagent, and detecting or quantitating the specific

III
specific binding agent of similar or of complementary binding specificity as the analyte, and a label (e.g. a radioactive or enzyme label) for the second reagent.








Fig. 1.


SUBSTITUTE SHEET (RULE 26)

Fig.2.3/10
PCT/GB95/00238**Fig.3.****Fig.4.****Fig.9.**


SUBSTITUTE SHEET (RULE 26)

SUBSTITUTE SHEET (RULE 26)

6/10

Fig. 6.

7/10

Fig. 7.Expression of ACT-4-h-1
in Stable Cell Lines

3

.0H3

CHO

99. Стартует ли в России политическая партия, созданная на базе Национального фронта? 78

Fig. 10.

Fig. 8


8 / 10

WO 95/21915

PCT/CB95/00238

PCT/GB95/00238

WO 9521915



SUBSTITUTE SHEET (RULE 26)

W09521915

PCT/GB95/00238

Fig. 10 (Cont.).

SUBSTITUTE SHEET (B)(II) E 26)

1082

INTERNATIONAL SEARCH REPORT

PCT/gB 95/00238

Cited (continued) DOCUMENTS CONSIDERED TO BE RELEVANT Category ^a		Reference to document No.
X	TISSUE ANTIGENS, vol. 42, no. 4, October 1993 COPENHAGEN, DENMARK, page 253 W. GODFREY ET AL. 'Molecular cloning of a cDNA encoding the human homolog of the rat OK-40 antigen.' cited in the application see abstract AA057	1,7,12, 21, 33-35, 38,39, 41,66
P,X	THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 180, no. 2, 1 August 1994 NEW YORK, NY, USA, pages 757-762, W. GODFREY ET AL. 'Identification of a human OK-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor.' see the whole document	1-3, 5-12,21, 33-36, 38,39, 41, 52-55, 57,61, 63-65